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ABBREVIATIONS 
 
ACh Acetylcholine 
ANOVA Analysis of variance 
BZD Benzodiazepine 
β-CCM Methyl-β-carboline-3-carboxylate 
CNS Central nervous system 
DEPC Diethylpyrocarbonate 
DMSO Dimethyl sulfoxide 
EC50 Half maximal effective concentration 
EC3-10, EC5-10 Effective concentration inducing 3-10% (5-10%) of the maximal 
response 
EtOAc Ethyl acetate 
GABA Gamma-aminobutyric acid 
GABAA receptor GABA type A receptor 
HPLC High-performance liquid chromatography 
HPLC-PDA-MS High-performance liquid chromatography − photodiode-array 
detection − mass spectrometry 
IACh ACh-induced cationic current 
IGABA GABA-induced chloride currents 
KV Voltage-gated potassium channel 
LHA Liquid handling arm 
LOQ Limit of quantification 
MeOH Methanol 
MS-222 Methane sulfonate salt of 3-aminobenzoic acid ethyl ester 
nAChR Nicotinic acetylcholine receptor 
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OPA o-phthaldialdehyde 
T Transmembrane domain 
t10-90% The time of current rise/decrease from 10 to 90% 
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1 INTRODUCTION 
 
1.1 GABAA receptors: role in the CNS  
GABA (C4H9NO2) is the main and the most widely distributed inhibitory 
neurotransmitter in the CNS (for review: Bormann, 2000; Sieghart and Ernst, 2005; 
Nutt, 2006; Clayton et al., 2007; Olsen and Sieghart, 2008; Sarto-Jackson and 
Sieghart, 2008), nevertheless it has been recently suggested that it might mediate 
excitation in some immature and adult neurons (Ben-Ari, 2002; Beg and Jorgensen, 
2003; Ben-Ari et al., 2007; Cancedda et al., 2007). 
Contingent on the specific brain region, GABA is used as a transmitter in about 
20 - 50% of all neuronal synapses (for review: Hevers and Lüddens, 1998; Sieghart 
et al., 1999; Bateson, 2004; Nutt, 2006). GABA mediates its action by interacting with 
GABAA receptors representing a ligand-gated chloride channels (for review: 
Bormann, 2000; Rudolph et al., 2001; Sieghart and Ernst, 2005; Olsen and Sieghart, 
2008; Sarto-Jackson and Sieghart, 2008). 
Different clinically important drugs such as benzodiazepines, barbiturates, 
neurosteroids, general anaesthetics and convulsants have been demonstrated to 
exert their effects by interacting with distinct allosteric binding sites on GABAA 
receptors (for review: Sieghart et al., 1999; Bateson, 2004; Sieghart and Ernst, 2005; 
Clayton et al., 2007; Jacob et al., 2008; Olsen and Sieghart, 2008; Sarto-Jackson 
and Sieghart, 2008). 
Because of their wide distribution throughout the CNS, GABAA receptors are 
involved or play a key role in actually all brain physiological functions: controlling the 
excitability, modulation of anxiety, muscle tone, sleep, feeding and drinking 
behaviour, circadian rhythms, cognition, vigilance, memory and learning (for review: 
Sieghart et al., 1999; Rudolph et al., 2001; Sieghart and Ernst, 2005; Möhler, 2006; 
Nutt, 2006; Clayton et al., 2007; Olsen and Sieghart, 2008; Sarto-Jackson and 
Sieghart, 2008). 
Incorrect functioning of GABAA receptors leads to CNS diseases such as 
anxiety, epilepsy, insomnia, depression and bipolar disorder, schizophrenia, as well 
as mild cognitive impairment and Alzheimer's disease, diseases associated with 
memory deficits (for review: Rudolph et al., 2001; Möhler, 2006; Nutt, 2006; Clayton 
et al., 2007; Jacob et al., 2008). It was also reported that GABAA receptors play a key 
role in mediating the effects of ethanol in the CNS and thus being involved in alcohol 
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abuse (for review: Aguayo et al., 2002; Davies, 2003; Clayton et al., 2007; Wallner 
and Olsen, 2008). 
 
1.2 Structure of GABAA receptors 
GABAA receptors belong to the large “Cys-loop” superfamily of ligand-gated ion 
channels, which includes also nicotinic acetylcholine receptors, glycine receptors and 
the serotonin type 3 (5HT3) receptors (for review: Möhler, 2006; Jacob et al., 2008; 
Olsen and Sieghart, 2008; Sarto-Jackson and Sieghart, 2008). It is believed that 
GABAA receptor complex is built from five membrane-crossing subunits that are 
arranged to form an intrinsic anion-conducting channel (Fig. 1.1; for review: 
Bormann, 2000; Rudolph et al., 2001; Sieghart and Ernst, 2005; Möhler, 2006; Nutt, 
2006; Clayton et al., 2007; Olsen and Sieghart, 2008; Sarto-Jackson and Sieghart, 
2008).  
 
 
 
Fig. 1.1 Schematic representation of the GABAA receptor complex comprising 2α, 2β 
and 1γ subunits. Agonist binding occurs at the interface between the α and β 
subunits and leads to the opening of the channel, allowing the rapid influx of Cl- into 
the cell and resulting in neuronal hyperpolarisation. BZDs bind at the interface 
between the α and γ subunits and allosterically modulate GABAA receptor by 
increasing its affinity to agonist resulting in potentiation of IGABA (for review: Nutt, 
2006; Jacob et al., 2008). 
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Nineteen isoforms of mammalian GABAA receptor subunits have been cloned: 
α1-6, β1-3, γ1-3, δ, ε, π, ρ1-3 and θ (Simon et al., 2004; for review: Barnard et al., 1998; 
Sieghart and Ernst, 2005; Nutt, 2006; Clayton et al., 2007; Olsen and Sieghart, 2008; 
Sarto-Jackson and Sieghart, 2008), which are classified according to sequence 
homology (≈ 70% in a subunit class and ≈ 30% between classes; see Hevers and 
Lüddens, 1998; Chebib and Johnston, 1999; Bateson, 2004; Clayton et al., 2007; 
Olsen and Sieghart, 2008 for a review). The most prevalent GABAA receptor 
composition in vivo (about 60% of all GABAA receptors, Table 1.1) consists of α1, β2 
and γ2 subunits and that the most likely stoichiometry is two α subunits, two β 
subunits and one γ subunit (Fig. 1.1; Baumann et al., 2002; for review: Sieghart and 
Sperk, 2002; Möhler, 2006; Nutt, 2006; Jacob et al., 2008; Olsen and Sieghart, 2008; 
Sarto-Jackson and Sieghart, 2008). Minor GABAA receptors subtypes contain α2, β3, 
γ2 and α3, βn, γ2 subunits and represent ≈ 15 – 20% and ≈ 10 – 15% of the total, 
respectively (Table 1.1). Receptors incorporating subunits such as α4, α5, α6, β1, γ1, 
γ3, δ, ε and θ are even less numerous, however, they might have some important 
pharmacological properties (Table 1.1). The δ, ε, π or θ subunit can substitute for the 
γ subunit (Nutt, 2006; Jacob et al., 2008). The ρ subunits form homomeric and 
heteromeric GABA-gated chloride channels (sometimes referred as GABAC 
receptors), which have distinct pharmacological properties (for review: Barnard et al., 
1998; Bormann, 2000; Möhler, 2006; Sarto-Jackson and Sieghart, 2008). 
The membrane topology of a single subunit of a GABAA receptor is shown in 
Fig. 1.2. Each subunit comprises a large extracellular N-terminal domain, four 
membrane spanning domains (T1 – T4), which are linked by a small intracellular T1-
T2 loop, an extracellular T2-T3 loop, a large intracellular T3-T4 loop, and a small 
extracellular C-terminus. The second membrane spanning domain (T2) provides the 
lining of the chloride pore (for review: Bormann, 2000; Möhler, 2006; Jacob et al., 
2008; Olsen and Sieghart, 2008;). The N-terminal parts of α and β subunits 
participate in the formation of the two agonist-binding sites (Sigel et al., 1992; Amin 
and Weiss, 1993; Boileau and Czajkowski, 1999; Wagner and Czajkowski, 2001; 
Newell and Czajkowski, 2003). GABA binding to these sites leads to pore opening.  
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Fig. 1.2 Schematic drawing of the membrane topology of a single subunit of a 
GABAA receptor. Transmembrane domains (T1 – T4), extracellular C- and N-
terminus, extracellular T2-T3 loop, and intracellular T1-T2 and T3-T4 loops are 
shown.  
 
1.3 Function and localization of specific GABAA receptor subtypes 
The subunit composition determines GABA sensitivity, sensitivity for 
benzodiazepines, barbiturates, neurosteroids and anaesthetics (see Sieghart, 1995; 
Hevers and Lüddens, 1998; Sigel, 2002 for review; Ernst et al., 2003, 2005) and also 
the gating properties of GABAA receptors (Boileau et al., 2003, 2005; Feng et al., 
2004). 
Table 1.1 illustrates pharmacological characteristics and in vivo localization of 
the different subunit compositions (see Möhler, 2006 for review): 
 
Table 1.1 
Composition Pharmacological 
characteristics 
Regional and neuronal 
localisation 
Subcellular 
localization 
α1β2γ2 
Major subtype (60% of all 
GABAA receptors). 
Mediates the sedative, 
amnestic and, to a large 
extent, the anticonvulsant 
action of benzodiazepine 
Cerebral cortex (layer I–VI, 
selected interneurons and 
principal cells); hippocampus 
(selected interneurons and 
principal cells); pallidum striatum 
(interneurons); thalamic relay 
Synaptic (soma 
and dendrites) and 
extrasynaptic in all 
neurons with high 
expression 
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site agonists. High affinity 
for classical 
benzodiazepines, zolpidem 
and the antagonist 
flumazenil 
nuclei; olfactory bulb (mitral cells 
and interneurons); cerebellum 
(Purkinje cells and granule cells); 
deep cerebellar nuclei; amygdala; 
basal forebrain; substantia nigra 
pars reticulata; inferior colliculus; 
brainstem 
α2β3γ2 
Minor subtype (15–20%). 
Mediates anxiolytic action 
of benzodiazepine site 
agonists. High affinity for 
classical benzodiazepine 
agonists and the 
antagonist flumazenil. 
Intermediate affinity for 
zolpidem 
Cerebral cortex (layers I–IV) 
hippocampal formation (principal 
cells mainly on the axon initial 
segment); olfactory bulb (granule 
cells); striatum (spiny stellate 
cells); inferior olivary neurons 
(mainly on dendrites); 
hypothalamus; amygdala 
(principal cells); superior 
colliculus; motor neurons 
Mainly synaptic, 
enriched in axon 
initial segment of 
cortical and 
hippocampal 
pyramidal cells 
α3βnγ2 
Minor subtype (10–15%). 
High affinity for classical 
benzodiazepine agonists 
and the antagonist 
flumazenil. Intermediate 
affinity for zolpidem 
Cerebral cortex (principal cells in 
particular in layers V and VI; 
some axon initial segments); 
hippocampus (some hilar cells); 
olfactory bulb (tufted cells); 
thalamic reticular neurons; 
cerebellum (Golgi type II cells); 
medullary reticular formation; 
inferior olivary neurons; 
amygdala; superior colliculus; 
brainstem; spinal cord; medial 
septum; basal forebrain 
cholinergic neurons; raphe and 
locus coeruleus (serotoninergic 
and catecholaminergic neurons) 
Mainly synaptic, 
including some 
axon initial 
segments; 
extrasynaptic in 
inferior olivary 
neurons 
α4βnδ 
Less than 5% of all 
receptors. Insensitive to 
classical benzodiazepine 
agonists and zolpidem 
Dentate gyrus (granule cells); 
thalamus 
Extrasynaptic (no 
direct 
morphological 
evidence) 
α5β3γ2 
Less than 5% of all 
receptors; high affinity for 
classical benzodiazepine 
agonists and the 
antagonist flumazenil. Low 
affinity for zolpidem 
Hippocampus (pyramidal cells); 
olfactory bulb (granule cells, 
periglomerular cells); cerebral 
cortex; amygdala; hypothalamus; 
superior colliculus; superior 
olivary neurons; spinal trigeminal 
neurons; spinal cord 
Extrasynaptic in 
hippocampus, 
cerebral cortex, 
and olfactory bulb; 
synaptic and 
extrasynaptic in 
spinal trigeminal 
nucleus and 
superior olivary 
nucleus 
α6β2,3γ2 
Less than 5% of all 
receptors. Insensitive to 
classical α6β2,3δ 
benzodiazepine agonists 
and zolpidem. Minor 
population. Lacks 
benzodiazepine site 
Cerebellum (granule cells); dorsal 
cochlear nucleus 
Synaptic 
(cerebellar 
glomeruli) and 
extrasynaptic on 
granule cell 
dendrites and soma 
 
from Möhler, 2006 
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1.4 BZD modulation of GABAA receptors: structural basis 
Benzodiazepines produce their action on the CNS by binding to a modulatory site of 
the GABAA receptors that is separated from the agonist-binding sites (Fig. 1.1) and 
allosterically modulating GABA-induced chloride current (see Nutt, 2006 for review; 
Hanson and Czajkowski, 2008). These drugs change activation of GABAA receptors 
either by increasing apparent affinity of at least one agonist-binding site (see 
Gallager and Tallman, 1983 for review; Serfozo and Cash, 1992; Lavoie and 
Twyman, 1996; Nutt, 2006 for review) or affecting the pore opening (Baur and Sigel, 
2005). GABAA receptors carry two GABA-binding sites at the respective α/β 
interfaces (see e.g., Olsen and Sieghart, 2008 for review; Fig. 1.1). By selective 
disruption of the one or the other of these sites in concatenated GABAA receptors it 
recently has been demonstrated (Baur and Sigel, 2005) that chloride currents were 
potentiated by diazepam in both cases. 
The BZD-binding site is formed by residues located in six extracellular regions 
(loops A-F) between α and γ subunits of the GABAA receptor (see Sigel, 2002 for 
review; see also Tan et al., 2007; Fig. 1.3). 
 
 
adapted from Hanson and Czajkowski, 2008 
 
Fig. 1.3 Homology model of the α1/γ2 interface of the GABAA receptor (α1 subunit is 
highlighted in red whereas γ2 subunit is blue). BZD-binding site is represented by 
loops A – E (yellow) and loop F (green). The latter is believed to be involved in 
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conformational changes initiated after BZD binding (Hanson and Czajkowski, 2008). 
Cell membrane is marked by the dashed lines. 
 
The structural elements that transduct BZD binding to positive or negative modulation 
of IGABA are substantially unknown. Boileau et al. (1998) and Boileau and Czajkowski 
(1999) identified residues that are required for modulation of IGABA by BZD-positive 
modulators using γ2/α1 chimeric protein combinations. Key residues were located 
near the channel domain of the γ2 subunit namely in the pre-T1 area (γ2-K41 – γ2-
W82 and γ2-R114 – γ2-D161 regions), the extracellular end of T2 (γ2-T281, γ2-I282), 
and the T2-T3 extracellular loop (γ2-S291). The authors also observed that the 
specified residues (γ2-T281, γ2-I282 and γ2-S291) were not involved in inhibition of 
IGABA by the BZD site inverse agonist DMCM and came to the conclusion that 
negative and positive allosteric modulations have distinct structural determinants 
(Boileau and Czajkowski, 1999). In later studies Hanson and Czajkowski (2008) 
using modulation of IGABA by positive (flurazepam and zolpidem) and negative 
(DMCM) BZD ligands revealed that residuces in γ2-Q182 – γ2-R197 region (Loop F, 
see Fig. 1.3) are crucial in defining the BZD efficacy. They suggested that the loop F 
is involved in the modulator-induced conformational changes at the BZD-binding site. 
Jones-Davies et al. (2005) identified several key regions in the γ2L subunit that 
play a role in gating. By making use of different γ2L/δ chimeras these authors located 
two areas of interest: a sequence stretch in T1, C-terminal region of T2 and the loop 
between T2 and T3 as functional units that are involved in BZD modulation. Their 
data suggest that the following of residues: γ2-Y235, γ2-F236, γ2-T237 in T1; γ2-S280, 
γ2-T281 and γ2-I282 located in T2 (see Boileau and Czajkowski, 1999) as well as the 
entire loop T2-T3 are involved in transducing the binding of BZDs to increased 
gating.  
Using the cysteine accessibility method Kloda and Czajkowski (2007) provided 
evidence that the residues in the α1-M113 – α1-L132 region (loop E) of the GABA-
binding site move in response to BZD modulation. 
 
1.5 Estimation of BZD efficiency 
Heterologous expression systems are the basis for drug development and 
pharmacological characterization of different GABAA receptor subtypes. Transfection 
of mammalian cells or cRNA injection into Xenopus oocytes with α1, β2 and γ2 
subunits may, however, result in different mixtures of α1β2 and α1β2γ2 receptors 
 14 
(Baumann et al., 2001; Boileau et al., 2002, 2003) which complicates the unequivocal 
estimation of potencies and efficiencies of BZDs in heterologous expression systems. 
This problem can partially be overcome by injecting larger amounts of γ2 subunit 
cRNA (Boileau et al., 2002) or, alternatively, by making use of concatenated GABAA 
receptor subunits (Baumann et al., 2002; Minier and Sigel, 2004 for review; Boileau 
et al., 2005). 
We have previously reported that different efficiencies of BZDs to enhance 
chloride currents through GABAA receptors comprising γ1 or γ2S subunits are related 
to their ability to shift the GABA concentration–response curves towards higher 
GABA sensitivities (Khom et al., 2006). Here an approach for estimating BZD 
efficiency is derived from analysis of the relation between γ-induced inhibition of 
GABA sensitivity and IGABA potentiation by three BZDs (triazolam, clotiazepam and 
midazolam) in oocytes expressing different populations of α1β2 and α1β2γ2S(γ1) 
subunit receptors. 
 
1.6 Searching for new GABAA receptor ligands in plants and fungi 
GABAA receptors are modulated by numerous structurally distinct substances 
including clinically important drugs such as benzodiazepines, barbiturates, 
neurosteroids and various general anaesthetics (for review: Sieghart et al., 1999; 
Bateson, 2004; Sieghart and Ernst, 2005; Clayton et al., 2007; Jacob et al., 2008; 
Olsen and Sieghart, 2008; Sarto-Jackson and Sieghart, 2008). The use of the most 
frequently prescribed benzodiazepines is, however, associated with a number of 
unwanted side effects such as anterograde amnesia, reduced coordination, cognitive 
impairment, increased accident proneness and, most importantly, development of 
dependence and abuse liability (see Hobbs et al., 1996; also Möhler et al., 2002; 
Sieghart and Ernst, 2005; Whiting, 2006 for review). Receptor subtype-selective 
GABAA ligands that are expected to produce fewer side effects than the 
benzodiazepines are currently in various stages of preclinical and clinical 
development (see Whiting, 2006 for review). The number of structural templates is, 
however, limited and systematic screening of alternative sources for drug leads may 
expand the repertory of structures that could be developed. The occurrence of 
GABAA receptor ligands is reportedly high in plant extracts (Medina et al., 1989), and 
a number of structurally diverse natural products are known to interact with GABAA 
receptors. Antagonists and channel blockers include compounds such as bicuculline, 
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picrotoxin (for review: Stephenson, 1995; Bormann, 2000; Olsen and Sieghart, 2008) 
and thujone (Höld et al., 2000), but these molecules are only of interest for basic 
science and not for drug development. The biflavone amentoflavone (Nielsen et al., 
1998), tetrahydroberberines, and simple flavones (Ai et al., 1997; Tsang and Xue, 
2004 for review) have been reported to interact with GABAA receptors. Khom et al. 
(2007) recently reported that valerenic acid, a compound from the roots of Valeriana 
officinalis, allosterically modulates GABAA receptors exclusively containing β2 or β3 
subunits. Chloride currents through GABAA receptors incorporating a β1 subunit were 
not stimulated (Khom et al., 2007). These and other data support the existence of 
natural products with subtype specific action on GABAA receptors (Huen et al., 2003; 
Baur et al., 2005; Hansen et al., 2005). 
Considering the therapeutic potential of subtype selective GABAA modulators 
and the few synthetic leads and drug candidates in development, a systematic 
screening for natural product leads appears worthwhile. Past efforts for identifying 
GABAA ligands from plant extracts were scattered and focused mainly on few 
compound classes such as flavonoids and alkaloids (see Tsang and Xue, 2004 for 
review). Also, classical activity-guided preparative isolation of compounds from an 
extract tested active is tedious and time-consuming. In contrast, HPLC-based activity 
profiling combines the speed and separation power of HPLC with structural 
information of on-line spectroscopy and miniaturized bioassays (Potterat and 
Hamburger; 2006). Hamburger and coworkers have previously implemented and 
used this approach for the profiling of plant extracts for various pharmacological 
targets including cyclooxygenase-2, inducible NO synthase, leukocytic elastase and 
monoamine oxidase B in cell-based and cell-free assay systems (Danz et al., 2001; 
Dittmann et al., 2004; Hamburger et al., 2006).  
For the purpose of a medium-throughput search for new GABAA receptor 
ligands, we here describe the implementation and validation of an efficient profiling 
approach for plant and fungal extracts which combines HPLC-PDA-MS with an 
automated functional assay using Xenopus oocytes expressing GABAA receptors of 
the desired subtype composition. 
 
1.7 Pharmacological properties of GABAA receptors containing γ1 subunits 
Compared to the γ2 subunit, which is ubiquitously expressed in the central nervous 
system the γ1 subunit is expressed in only a few areas of the brain such as the 
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amygdala (central and medial nuclei), the pallidum, the septum, the substantia nigra 
and the thalamus (centrolateral and medial nuclei) (Pirker et al., 2000; for review: 
Korpi et al., 2002; Sieghart and Ernst, 2005). Compounds selectively interacting with 
receptors containing γ1 subunits, thus, might have a substantial clinical potential. 
Little is known about the pharmacological profile of GABAA channels composed 
of α1, β2 and γ1 subunits. Ymer et al. (1990) observed a loss in affinity for the 
benzodiazepine antagonist flumazenil and the inverse agonist DMCM, when the γ1 
was substituted for γ2 in α1β1γ2 receptors. Negative modulatory effects of Ro15-4513, 
β-CCM and DMCM for GABAA receptors composed of α1/2/3β1γ2 subunits are 
changed to positive modulatory in α1/2/3β1γ1 receptors (Puia et al., 1991; Wafford et 
al., 1993). Benke et al. (1996) observed a low affinity for clonazepam, zolpidem and 
flunitrazepam, and apparent insensitivity for flumazenil and Ro15-4513 for γ1-
containing receptors. Wafford et al. (1993) demonstrated a reduced enhancement of 
chloride currents through α3β2γ3 by diazepam, clonazepam and bretazenil compared 
to α3β2γ2 and a negative modulatory effect of zolpidem for α2β1γ1 and alpidem for 
α3β1γ1 receptors. 
Overall, in 4 different studies a total of 14 compounds from 5 different 
compound classes have been investigated so far for their ability to modulate GABAA 
receptors containing γ1 subunits. Unfortunately, most of these studies were carried 
out under different experimental conditions and with receptors containing different α 
and β subunits combined with γ1. Thus, the relative efficacies of these compounds for 
αβγ1 are not comparable (Hevers and Lüddens, 1998). 
The modulation of α1β2γ1 receptors expressed in Xenopus oocytes by 21 
compounds comprising distinct chemical structures was analyzed in the present 
study.  
 
1.8 Oocyte perfusion systems: different approaches 
Xenopus laevis oocytes are extensively used as heterologous expression system for 
studies of voltage- and ligand-gated ion channels due to their ability to translate 
injected foreign RNA into proteins and form functional receptors and channels 
(Baumgartner et al., 1999; Weber, 1999 for review; Dascal, 2001; Buckingham et al., 
2006 for review; Cohen and Zilberberg, 2006).  
Being targets for a large number of therapeutic drugs, ion channels expressed 
in Xenopus oocytes are of interest for drug discovery studies (Soria and Cena, 1998, 
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Dunlop et al., 2008 for review). Most of these studies are performed by means of the 
two-microelectrode voltage clamp technique (Dascal, 1987 for review; Stühmer, 
1992; Stühmer and Parekh, 1995; Baumgartner et al., 1999; Dascal, 2001; Cohen 
and Zilberberg, 2006; see schematic drawing in Fig. 1.4). The development of 
automated procedures to increase throughput and to standardize drug application to 
oocytes during voltage-clamp experiments is, therefore, of prime interest. 
 
 
 
Fig. 1.4 Two-microelectrode voltage clamp method scheme. The membrane of the 
oocyte is penetrated by two microelectrodes, one for voltage sensing (µE1) and one 
for current injection (µE2). The membrane potential as measured by the voltage-
sensing electrode (µE1) is compared with a command voltage (Vc), and the 
difference is brought to zero by a control amplifier. The injected current is monitored 
to provide a measure of the total membrane current (from Baumgartner et al., 1999). 
 
 18 
In “conventional” two-microelectrode experiments, oocytes are placed in a 
circular or elongated bath with one or several perfusion inlets from one side and a 
drain on the opposite side of the chamber. 
Although widely used, these perfusion systems have a number of limitations:  
• number of tested compounds is restricted by the number of perfusion 
tubes connected to respective reservoirs; 
• frequent replacement of these, usually plastic, perfusion tubes due to their 
possible contamination by e.g., lipophilic compounds; 
• filling the inlet tubes completely to prevent airgaps in the perfusion system 
and as a result - waste of valuable compounds; 
• and finally, large bath volumes and slow perfusion rates prevent fast and 
timed applications of neurotransmitters (as required for studies of ligand-gated 
ion channels) resulting in apparently slow activation of the channels and 
substantial receptor desensitization during the chamber perfusion leading 
to an underestimation of the peak current values and inaccurate 
estimation of the kinetic properties of ligand-gated ion channels. 
Different methods have been developed in recent years to overcome problems 
associated with “conventional” bath perfusion. Madeja et al. (1991) report an oocyte 
perfusion time of less than 800 ms for a system where Xenopus oocytes are inserted 
into a vertical perfusion tube and fast exchange is achieved by sucking test solution 
into the tube. In a later study (Madeja et al., 1997) the authors show that drug 
application to oocytes can be significantly accelerated if the follicular tissue of the 
oocyte is carefully removed. The authors report mean times for half maximal 
suppression of potassium conductance’s by 1 mM/l tetraethylammonium of 70 ms. 
The “cut open” oocyte voltage clamp technique enables high resolution voltage 
clamp measurements and fast drug application since only part of the oocyte surface 
is perfused (Costa et al., 1994). A vertical oocyte perfusion system was described by 
Joshi et al. (2004) who estimated a solution exchange within about 400 ms by 
analyzing the rise time of currents through 5-HT3 receptors. Rettinger and 
Schmalzing (2003) reported mean rise times for 10 – 90% current increase through 
nAChRs within approximately 150 ms by applying the agonist via a manifold made of 
glass capillaries. Switching between solutions was attained by computer-controlled 
magnetic valves suggesting that this method can be partially automatized.  
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Several automated systems for voltage clamp experiments on Xenopus oocytes 
have been developed (Schnitzler et al., 2003; OpusXpress, Molecular Devices Corp. 
http://www.moleculardevices.com/pages/instruments/opusxpress.html; Trumbull et 
al., 2003). The rate of solution exchange of these systems is either not exactly 
specified or slow (ranging between 1 – 2 seconds, see Schnitzler et al., 2003; 
Trumbull et al., 2003 for review). Kinetic studies on ligand-gated channels can, 
however, only be performed if the neurotransmitters are applied by fast bath 
perfusion in “concentration jumps”.  
Automated fast perfusion system for drug screening on voltage- and ligand-
gated ion channels using two-microelectrode voltage clamp technique that is 
developed and described in the present study was based on the work of Prof. Hering 
(1998). He minimised the amount of test solution in experiments on oocytes by 
constructing a glass covered perfusion chamber with two angular holes in the plate 
enabling microelectrode access to the oocyte. Drugs or neurotransmitters were 
applied into a small funnel (≈ 50 µl) surrounding one of the microelectrodes and fast 
oocyte perfusion rates (t10-90% = 200 – 400 ms) were achieved.  
Further development of this technique that is described in Khom et al. (2006) led 
to a new chamber type where both holes in the glass plate (and the inserted 
microelectrodes) were surrounded by the funnel. This modification enabled 
substantially faster oocyte perfusion rates (t10-90% ≈ 140 ms, see Khom et al., 2006). 
Even faster perfusion rates (t10-90% ≈ 50 ms) were achieved by placing the oocyte on 
a cylindrical holder and thus enabling vertical flow of test solution (Baburin et al., 
2006).  
The basic features of the novel system are illustrated in experiments on nAChR 
and Kv1.1 channels. It is also demonstrated how compound delivery to the perfusion 
chamber can be automated by means of a standard pipetting workstation. 
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1.9 Aims of the work  
 
• To develop a screening system for oocytes that combines the advantages of 
fast perfusion (“concentration jump” ligand applications) and automation of 
drug delivery. 
 
• To establish and validate an efficient profiling approach for plant and fungal 
extracts, which combines HPLC-PDA-MS with an automated functional assay 
using Xenopus oocytes expressing GABAA receptors of the desired subtype 
composition. 
 
• To gain insight into the largely unknown pharmacological profile of GABAA 
receptors comprising γ1 subunits by investigating their modulation by different 
ligands from 12 structural classes making use of the two-microelectrode 
voltage clamp method and the novel oocyte screening system.  
 
• To develop an approach for estimation of BZD efficiency that accounts for 
mixed population of GABAA receptors containing α1β2 or α1β2γ2S(γ1) subunits 
heterologous expression systems. 
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2 MATERIALS AND METHODS 
 
2.1 Chemicals 
Compounds used in the present study were obtained from the following sources: 
flunitrazepam (7-nitro-1,3-dihydro-1-methyl-5-o-fluorophenyl-2H-1,4-benzodiazepin-
2-one), diazepam (7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-
one), flurazepam (7-chloro-1,3-dihydro-1-ethylaminodiethyl-5-o-fluorophenyl-2H-1,4-
benzodiazepin-2-one), midazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-
imidazo[1,5-a][1,4]benzodiazepine), flumazenil (ethyl-8-fluoro-5,6-dihydro-5-methyl-6-
oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate) and bretazenil (t-butyl(s)-8-
bromo-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-
c][1,4]benzodiazepine-1-carboxylate) were from Hoffmann La Roche (Basel, 
Switzerland); L-655,708 (ethyl-7-methoxy-11,12,13,13a-tetrahydro-9-oxo-9H-
imidazo[1,5-a]pyrrolo[2,1-c] [1,4]benzodiazepine-1-carboxylate) was purchased from 
Tocris Cookson Inc. (Bristol, UK); clotiazepam (5-(2-chlorophenyl)-7-ethyl-1,3-
dihydro-1-methyl-2H-thieno[2,3-e][1,4]diazepin-2-one) was from Troponwerke GmbH 
(Köln, Germany); clobazam (7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-
2,4(3H,5H)-dione) was from Sanofi-Aventis (Bridgewater, NJ, USA); triazolam (8-
chloro-6-(2-chlorophenyl)-1-methyl-4H-1,2,4-triazolo[4,3-a][1,4]benzodiazepine) was 
from Sigma (Vienna, Austria); DMCM (methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-
carboxylate) was from Ferrosan (Soeborg, Denmark); CGS 9896 (2-(4-chlorophenyl)-
pyrazolo[4,3-c]quinolin-3-one) and CGS 20625 (2-(4-methoxyphenyl)-
2,3,5,6,7,8,9,10-octahydro-cyclohepta-(b)pyrazolo[4,3-d]pyridin-3-one) were from 
Novartis (Basel, Switzerland); zolpidem (N,N,6-trimethyl-2-(4-
methylphenyl)imidazo[1,2-a]-pyridine-3-acetamide) was from Synthelabo Recherche 
(Bagneux, France); Cl 218,872 (3-methyl-6-[3-trifluoromethyl-phenyl]-1,2,4-
triazolo[4,3-b]pyridazine) was from American Cyanamide Comp. (Wayne, NJ, USA); 
Ru 31719 ((7-ethyl-5-methoxyimidazo[1,2-a]quinolin-2-yl)phenyl methanone), Ru 
32698 ((6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)phenylmethanone), 
Ru 33203 (5-(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-3-methyl-
[1,2,4]-oxadiazole) and Ru 33356 (2-(6-ethyl-7-methoxy-5-methylimidazo[1,2-
a]pyrimidin-2-yl)-4-methyl-thiazole) were from Roussel Uclaf (Romainville, France); 
PK 8165 (2-phenyl-4-(4-ethyl-piperidinyl)-quinoline) and PK 9084 (2-phenyl-4-(3-
 22 
ethyl-piperidinyl)-quinoline) were from Pharmuka Laboratories (Gennevilliers, 
France). 
For chemical structures, see Barnard et al. (1998), Ogris et al. (2004), Clayton 
et al. (2007). 
 
2.2 Plant material 
Dried roots of Notopterygium incisum were purchased from Yong Quan GmbH 
(Ennepetal, Germany). The roots of Valeriana officinalis were obtained from Alfred 
Galke GmbH (Gittelde/Harz, Germany). Voucher specimens (00 013 and 00127) are 
deposited at the herbarium of the Institute of Pharmaceutical Biology, University of 
Basel, Switzerland. 
 
2.3 Extraction technology§ 
The dried plant samples were ground with a Retsch ZM1 mill (Labequip LTD., 
Markham, Ontario, Canada). Extracts for the initial screening were prepared with an 
ASE 200 extraction system with solvent module (Dionex Corp., Sunnyvale, CA, USA) 
by consecutive extraction with dichloromethane, ethyl acetate and methanol. 
Extraction pressure was 120 bar and temperature was set at 70 °C. 
 
2.4 HPLC analysis§ 
2.4.1 General experimental procedures 
HPLC analysis was carried out with an Alliance™ system (Waters Corp., Milford, MA, 
USA) consisting of 2695 separation module and 996 photodiode array detector. Data 
acquisition and processing were performed using Empower software (Waters Corp., 
Milford, MA, USA). Microfractionation for profiling was carried out with an HP 1100 
series system (Agilent, Waldbronn, Germany) consisting of a degasser, a quaternary 
pump, a column oven and a diode array detector. An injection module 819 and a 
liquid handler 215 (Gilson, Mettmenstetten, Switzerland) were used as autosampler. 
LC/DAD/ESIMS analysis was performed on an HP 1100 system consisting of a 
degasser, a binary mixing pump, a column oven and a diode array detector, which 
are coupled to an Esquire 3000 Plus ion trap mass spectrometer (Bruker Daltonics, 
Bremen, Germany). Data acquisition and processing were performed on Hystar 3.0 
software (Bruker Daltonics, Bremen, Germany). A SunFire™ C18 (Waters Corp., 
Milford, MA, USA) (3.5 µm, 3.0 × 150 mm) and a SunFire™ Prep C18 (Waters Corp., 
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Milford, MA, USA) (5 µm, 10 × 150 mm) were used for analytical and semi-
preparative HPLC analysis, respectively. 
 
2.4.2 HPLC separation and microfractionation 
Microfractionation for activity profiling was performed using a SunFire™ Prep C18 (5 
µm, 10 × 150 mm) (Waters Corp., Milford, MA, USA). Gradient elution was carried 
out with acetonitrile containing 0.1% formic acid (solvent A) and water containing 
0.1% formic acid (solvent B). The flow rate was 7 ml/min. The extracts were 
dissolved in DMSO at concentrations of 15 mg/ml or 20 mg/ml, and the injection 
volumes varied between 200 µl and 500 µl. 
The EtOAc extract of Notopterygium incisum was separated with the following 
gradient: 30% A to 90% A for 30 min, followed by isocratic condition of 100% A for 5 
min. For activity profiling, aliquots of 200 µl, corresponding to 3 mg of EtOAc extract, 
were injected. For spiking experiments, 500 µg of magnolol was added. The column 
effluent was collected into test tubes (90 s per fraction), and a total of 20 fractions 
were obtained. The solvent was removed with an EZ-2 vacuum evaporator 
(Genevac, New York, USA). The dry films were redissolved in 1 ml of MeOH, and 
aliquots of 0.5 ml were dispensed into two vials and dried under N2 gas. As positive 
control, 500 µg of magnolol alone was separated under the same HPLC condition, 
and the collected magnolol fraction was divided into two vials after dryness. 
The EtOAc extract of Valeriana officinalis was separated using the following 
condition: 20% A to 100% A for 30 min, hold for 5 min. For activity profiling, aliquots 
of 500 µl, corresponding to 10 mg of EtOAc extract, were injected. Sample workup 
was as above. 
 
2.4.3 HPLC analysis of GABA 
Derivatization of GABA with OPA reagent and HPLC analysis were performed 
according to earlier protocols, with some modifications (Moret et al., 2005). To 40 µl 
of dissolved extracts (10 mg/ml in H2O or 50% aqueous MeOH), 200 µl of OPA (o-
phthaldialdehyde) reagent (Sigma-Aldrich, St. Louis, MO, USA) were added. The 
mixture was vortexed for 1 min and submitted to HPLC without further workup. The 
GABA derivatives were separated on a SunFire™ C18 column (3.5 µm, 3.0 × 150 
mm) using the following gradient condition: 13% A to 50% A for 25 min at a flow rate 
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of 0.5 ml/min, and UV detection at 340 nm. Solvent A was acetonitrile and solvent B 
consisted of 370 ml of water and 90 ml of phosphate buffer at pH 7.0, which was 
prepared by dissolving 3.54 g KH2PO4 and 5.66 g Na2HPO4 in 800 ml water, and 
adjusting to pH 7.0 with 50% NaOH (w/v) and diluting to 1 l with water. 
 
§This part of the work was performed by Kim HJ and Hamburger M (Institute of Pharmaceutical 
Biology, University of Basel, Basel, Switzerland) 
 
2.5 Expression of GABAA, nACh receptors and Kv1.1 channels 
Stage V-VI oocytes from Xenopus laevis were prepared and cRNA injected as 
previously described by Khom et al. (2006). Female Xenopus laevis (NASCO, Fort 
Atkinson, WI, USA) were anesthetized by exposing them for 15 minutes to a 0.2% 
MS-222 (Sigma, Vienna, Austria) solution before surgically removing parts of the 
ovaries. Follicle membranes from isolated oocytes were enzymatically digested with 
2 mg/ml collagenase (Type 1A, Sigma, Vienna, Austria). Synthesis of capped run-off 
poly(A+) cRNA transcripts was obtained from linearized cDNA templates (pCMV 
vector). One day after enzymatic isolation, the oocytes were injected with 50 nl of 
DEPC-treated water (Sigma, Vienna, Austria) containing different cRNAs at a 
concentration of approximately 300 – 3000 pg/nl per subunit. The amount of cRNA 
was determined by means of a NanoDrop ND-1000 (Kisker Biotech, Steinfurt, 
Germany). 
To ensure expression of the gamma subunit with different incorporation in the 
case of α1β2γ1 and α1β2γ2S receptors rat cRNAs were mixed in a ratios: 1:1:1, 1:1:3 
and 1:1:10, and for receptors comprising only α1 and β2 subunits, they were mixed in 
a ratio of 1:1 (Boileau et al., 2002). The double β2-23-α1 (β2-α1) and triple γ2-26-β2-23-
α1 (γ2-β2-α1) concatemers (kindly provided by E. Sigel), and the β2-R207C mutant 
(kindly provided by C. Czajkowski) have been described previously (Baumann et al., 
2001, 2002; Wagner et al., 2004). 
For expression of nAChRs the oocytes were injected with cRNA encoding for 
the four (αβγδ) subunits (gift of Dr. V. Witzemann) of the rat skeletal muscle nAChR 
(Witzemann et al., 1990). 
Kv1.1 channels (gift of B. Fakler) were expressed to evaluate the speed of 
solution exchange. 
Oocytes were stored at 18°C in ND96 solution (Methf essel et al., 1986). Voltage 
clamp measurements were performed between days 1 and 5 after cRNA injection. 
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2.6 Two-microelectrode voltage clamp studies 
Electrophysiological experiments were performed by the two-microelectrode voltage 
clamp method (see detailed description in Introduction section) making use of a 
TURBO TEC 01C amplifier (npi electronic GmbH, Tamm, Germany) at a holding 
potential of −70 mV (GABAA) or −80 mV (nAChR and Kv1.1) and pCLAMP 10 data 
acquisition software (Molecular Devices, Sunnyvale, CA, USA). Currents were low-
pass-filtered at 1 kHz and sampled at 3 kHz. Unless otherwise stated, the bath 
solution contained 90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM CaCl2 and 5 mM 
HEPES (pH 7.4). Electrode filling solution contained 2M KCl (GABAA and Kv 1.1); 2.8 
M CsCl, 0.2 M CsOH, 10 mM EGTA and 10 mM HEPES (pH 7.4, nAChR). 
Oocytes with maximal current amplitudes > 3 µA were discarded to exclude 
voltage clamp errors. 
 
2.7 Drug application  
Drugs, neurotransmitters or control solutions were applied by means of an automated 
fast perfusion system based on a TECAN Miniprep 60 pipetting workstation (see 
detailed description in Results section). To elicit IGABA or IACh the chamber was 
perfused with 120 µl of GABA-containing solution at volume rate between 300 and 
1000 µl/s. Duration of washout periods was extended from 3 to up to 30 minutes with 
increasing concentrations of applied GABA to account for slow recovery from 
increasing levels of desensitization. 
Stock solutions (10 mg/ml in DMSO) from the extract library were diluted to a 
concentration of 100 µg/ml with bath solution and then mixed with GABA EC3-10. 150 
µl of this solution were applied to the oocyte in the perfusion chamber at a speed of 
300 µl/s.  
Microfractions collected from the semi-preparative HPLC separations were 
dissolved in 30 µl DMSO and were mixed with 2.97 ml of bath solution. After addition 
of GABA EC3-10, 150 µl of this solution were applied to oocytes at a perfusion speed 
of 300 µl/s. 
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2.8 Analyzing concentration–response curves  
Enhancement of chloride currents by modulators of the GABAA receptor was 
measured at a GABA EC5-10, which is usually ranging between 3 and 8 µM GABA 
and is determined at the beginning of each experiment. 
Enhancement of the chloride current (IGABA) was defined as (GABA Comp)
GABA
I 1
I
+
− , 
where I(GABA + Comp) is the current response in the presence of a given compound, and 
IGABA is the control GABA current. To measure the sensitivity of the GABAA receptor 
for a given compound, it was applied for an equilibration period of 1 min before 
concomitant application of GABA EC5-10 and increasing concentrations of the 
compound.  
Concentration-response curves were generated, and the data were fitted by 
nonlinear regression analysis using ORIGIN software (OriginLab Corporation, 
Northampton, MA, USA). Data were fitted to the equation 
H
50
1
EC1 [Comp]
 
+  
 
n
, where 
EC50 is the concentration of the compound that increases the amplitude of the GABA-
evoked current by 50%, and nH is the Hill coefficient. In the case of IGABA modulation 
by triazolam, clotiazepam and midazolam at different GABA concentrations data 
were fitted to the equation 
H
50
1
EC1 [GABA]
 
+  
 
n
, where EC50 is the concentration of the 
GABA that increases the amplitude of the GABA-evoked current by 50%. 
Concentration-response data for each oocyte were normalized to the maximum 
control GABA current for that oocyte. 
Data are given as mean ± S.E. from at least four oocytes and ≥ 2 oocyte 
batches. Statistical significance was calculated using either unpaired Student t-test or 
t-test by ANOVA with a confidence interval of P < 0.05. Each data point in correlation 
analysis represents a pair of dose-response curves on one oocyte. 
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3 RESULTS 
 
3.1 Automating fast perfusion 
3.1.1 Construction of the perfusion chamber 
A schematic representation of the chamber is shown in Fig. 3.1A,B (cross-sectional 
and top view, respectively). As previously described (Hering, 1998), the voltage 
clamp experiments on Xenopus oocytes are performed in a small (≈ 15 µl) bath that 
is covered by a glass plate (7 in Fig. 3.1A,B). Two sloping inlet channels in the glass 
cover (diameter < 1 mm) enable access of the two microelectrodes (1 and 2 in Fig. 
3.1A–D) to the oocyte. A funnel reservoir (6 in Fig. 3.1A,B,D) for drug application 
surrounds the two microelectrodes. The principal modification compared to the 
previous chamber constructions (Hering, 1998; Khom, 2006) is the placement of the 
oocyte on a cylindrical holding device (15 in Fig. 3.1A) incorporated into the chamber 
bottom. The chamber outflow occurs via a circumferential gap (annular gap) around 
the cylinder (Fig. 3.1C). The perfusion gap with a ring-shaped cross-section is 
connected to the chamber outflow (12 in Fig. 3.1A,B). Rapid vertical perfusion of the 
oocyte occurs when a suction pulse of variable strength is applied to the outlet via a 
syringe pump (9 in Fig. 3.1A) of the pipetting workstation. The oocytes reside in a 
small well at the cylinder and two microelectrodes are inserted into the chamber via 
the glass plate. The vertical perfusion through the two symmetrically arranged 
channels for the microelectrode in the glass plate guarantees a high degree of 
stability during solution exchange. Neurotransmitters are rapidly washed by 
applications of control solutions (see, for example, Fig. 3.4A). Contamination of wash 
solution by remaining neurotransmitters or dilution of drugs or neurotransmitters by 
residual control solution is prevented by emptying the funnel via two funnel outlets (4 
and 5 in Fig. 3.1A) before the next sample is applied. 
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Fig. 3.1 Cross-section view (A) and top view (B) of the oocyte perfusion chamber. 
Two microelectrodes (1 and 2) are inserted via the sloping access inlets (8) through a 
glass cover plate (7) into the small (≈ 15 µl) oocyte chamber. Drug is applied by the 
tip of the liquid handling arm (3) of a TECAN Miniprep 60 to a funnel reservoir made 
of quartz (6) surrounding the microelectrode access holes. Perfusion of the oocyte 
(10) that is placed on a cylindrical holding device (15) is enabled by means of the 
syringe pump (9) of the Miniprep 60 connected to the chamber body (11) via the 
outlet (12). Residual solution is removed from the funnel before drug application via 
the funnel outlets (4 and 5). In addition to the ground reference electrode (13), the 
cylindrical holder for the oocyte contains a reference electrode (14) that serves as an 
extracellular reference for the potential electrode. Salt bridges can be inserted into 
the side outlet for the ground electrode (13). (C) Schematic drawing of the solution 
flow inside the perfusion chamber and in the annular gap around the cylinder with 
oocyte. (D) Photo of the oocyte perfusion chamber. An oocyte (10) is placed on a 
cylinder and impaled with two microelectrodes (1,2) surrounded by the funnel (6). 
 
3.1.2 Automation of drug application and washout 
To automate the oocyte perfusion, we connected the chamber outlet (D) to a syringe 
(P2) of a pipetting workstation (Miniprep 60, TECAN, Crailsheim, Germany) (Fig. 
3.2A). The different fluid handling procedures performed by the workstation include: 
(1) agonist/drug application to the funnel (F) by means of the liquid handling arm 
(LHA), (2) application of suction to the drain (D) and (3) removal of residual solution 
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from the funnel via two additional funnel outlets (FO) by means of a MiniWash pump 
module (MW) (TECAN, Crailsheim, Germany) (Fig. 3.2A). Simultaneous data 
recording was organized by corresponding software and hardware adaptations. To 
prevent mechanical disturbances during two-microelectrode voltage clamp 
measurements, the pipetting workstation and perfusion chamber were mounted on 
separate tables. 
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Fig. 3.2 (A) Schematic diagram of the liquid handling system connected to the 
perfusion chamber. Neurotransmitters or drugs are applied via the tip of the movable 
liquid handling arm (LHA). Dashed lines and arrows illustrate LHA movements. LHA 
is connected to a pump (P1) allowing aspiration and delivery of the desired volumes 
from the rack with tested solutions (R) to the funnel reservoir (F) of the perfusion 
chamber. The second syringe pump (P2) is connected to the chamber drain (D). This 
pump is also connected to a distilled water station (DW). Pump P2 provides a suction 
pulse to the outlet, permitting fast perfusion of the chamber. Residual volumes of test 
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solutions are removed from the chamber by means of a MiniWash pump module 
(MW) (TECAN). This module provides a standard suction pulse to the two funnel 
outlets (FO) that are operated ≈ 0.5 s before a new test solution is applied to the 
funnel that excluded mixing of test and wash solutions in the funnel. The outlets of 
the MiniWash pump module and the pump (P2) are connected to a waste container 
(W). Arrows indicate the direction of liquid flow in the tube system. (B) Schematic 
drawing of the tip of the liquid handling arm (left panel) and fragment of the tip with 
solutions inside (right panel). To shorten time between applications of different drugs 
or time between application of drug and washout, the drugs (D1 and D2) and the 
wash solution (WS) can be aspirated into the tip one after the other and separated 
from each other by air gaps (AG). (C) Block diagram of the protocol used for studies 
on ligand-gated channels. Each cycle (Cycle 1) starts with the standard cleaning step 
(Wash Tip) of the LHA tip in distilled water (Wash Tips procedure, see TECAN 
Gemini handbook). Control solutions for washout of drug and test solution (containing 
a drug or neurotransmitter) are subsequently aspirated [ASP(1) and ASP(2)] into the 
tip of LHA. Immediately before the test solution is applied, the residual solution is 
removed via the funnel outlets (residual solution removal, RSR) by means of MW. 
Application of test solution to the funnel (ATS) and immediate fast perfusion (FP) of 
the chamber are followed by the subsequent application of wash solution to the 
chamber (AWS) and rapid washout (FP). The next sequence of commands (Cycle 2) 
can then be executed. Control bath solution is aspirated and applied to the funnel, 
and the chamber is slowly perfused (SP, at 1 – 8 µl/s) to guarantee steady-state 
conditions throughout the experiment. Cycle 1 can be repeated user-defined 
depending on the number of drugs to be tested. 
 
3.1.3 Software for operating the pipetting workstation 
To adapt the pipetting robot for the needs of oocyte perfusion, “Robosoft 1.0” 
software (Fig. 3.3) for the TECAN workstation has been developed. The program is 
written in Visual Basic using TECAN communication protocol. It defines parameters 
such as (1) the number of chamber wash cycles, (2) perfusion volume, (3) perfusion 
speed, (4) timing of drug application and (5) the positions of the compound reservoirs 
and chamber funnel. The software enables the design of individual protocols for 
screening studies on ligand- or voltage-gated channels (Fig. 3.2C, 3.3). 
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Fig. 3.3 A screen shot of the main window of the TECAN workstation operating 
software “Robosoft 1.0”. Loaded protocol with a sequence of executable commands 
and its defined parameters are shown. 
 
3.1.4 Rate of solution exchange 
To compare the rate of oocyte perfusion in the chamber shown in Fig. 3.1 with 
previously described systems, we expressed muscle-type nicotinic ACh receptors 
and estimated the 10 – 90% current rise times during fast perfusion with agonist-
containing solution. To elicit IACh, 120 µl of ACh 30 µM-containing solution were 
applied to the funnel (6, Fig. 3.1A,B,D) and the chamber was perfused by a 
subsequent suction pulse applied to the channel outlet (12, Fig. 3.1A,B). To minimize 
diffusion of compound from the funnel into the chamber, we used glass covers with 
small openings for microelectrodes and applied the suction pulse immediately (< 1 s) 
after agonist delivery to the funnel. 
The rise time of IACh (30 µM acetylcholine) is dependent on the speed of 
chamber perfusion. Two examples are shown in Fig. 3.4B,C. Mean current rise times 
from 10 to 90% of 89.9 ± 5.7 ms (n = 7) (perfusion speed 300 µl/s) and 55.0 ± 1.3 ms 
(n = 5) (perfusion speed 600 µl/s) were estimated. Higher perfusion rates did not 
significantly accelerate current rise times (data not shown). 
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Fig. 3.4 (A) Receptor-activated ionic currents in oocytes expressing nACh receptors 
(α, β, γ and δ subunits). IACh were induced by subsequent applications of 100 nM, 
300 nM and 1 µM ACh to the same oocyte. (B) Upon application of 30 µM nACh with 
a chamber perfusion speed of 300 µl/s, IACh increased from 10 to 90% within 85 ms. 
(C) Upon application of 30 µM ACh with a chamber perfusion speed of 600 µl/s, IACh 
increased from 10 to 90% within 55 ms. 
 
To estimate the rate of solution exchange independent of the kinetics of ligand-
receptor interactions, we expressed Kv1.1 channels in Xenopus oocytes, applied 
voltage clamp steps from −80 to +20 mV, and analyzed the time course of current 
decay during a rapid increase of the extracellular potassium concentration from 1 to 
30 mM. Figure 3.5A illustrates a typical experiment. The current decrease at a higher 
time resolution is shown in Fig. 3.5B. The estimated mean current decline time t10-90% 
of 51.1 ± 5.1 ms (n = 7) at a perfusion rate of 600 µl/s was similar to the rise time of 
the agonist-induced current (Fig. 3.4C). A mean current decline time t10-90% of 81.2 ± 
12.1 ms (n = 5) was observed at a perfusion rate of 300 µl/s (data not shown). Faster 
perfusion rates (700 µl/s) did not significantly accelerate the current decrease time 
(t10-90% = 46.5 ± 2.8 ms; n = 5, data not shown). 
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Fig. 3.5 Estimation of the rate of solution exchange by “concentration jump” 
application of high-potassium solution during Kv1.1 recordings. (A) The extracellular 
potassium concentration was rapidly increased (chamber perfusion speed of 600 
µl/s) from 1 to 30 mM during a potassium outward current (voltage step from −80 to 
+20 mV) (thick line, 2). Superimposed current traces before (1) and after (3) the 
“concentration jump” are shown as dashed lines. (B) The time of current decrease 
from 10 to 90% (t10-90%) was taken as a measure of the volume rate of oocyte 
perfusion. 
 
3.1.5 Perfusion modes 
After an initial fast perfusion step for a “concentration jump” application of an agonist, 
the chamber is continuously perfused at slower rates between 1 and 8 µl/s to ensure 
steady-state conditions throughout the experiments (Fig. 3.6). During this period, the 
funnel can be refilled by the workstation depending on the experimental design (see 
Fig. 3.2C, for details). Before washout of agonist and/or drug or, alternatively, before 
a new compound is applied, the funnel is emptied via the two funnel outlets (4, 5 in 
Fig. 3.1A). 
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Fig. 3.6 Subsequent oocyte perfusion by 1 µM (left trace) and 300 nM (right trace) 
ACh at different perfusion rates. ACh application (1) and washout (2) were performed 
at 350 µl/s (“concentration jump” mode). Between the neurotransmitter applications, 
the chamber was perfused at low speed 8 µl/s (“slow perfusion” mode, (3)). 
 
3.1.6 Timed ligand applications 
The time between two ligand applications is defined by the time required for moving 
the motorized pipetting arm of the workstation (e.g., from the chamber to the 
reservoir and back to the chamber funnel; Fig. 3.2A). Shorter drug application 
intervals can be achieved, however, if several test and control solutions are aspirated 
consecutively (separated by air gaps) into the tip of the liquid handling arm (Fig. 
3.2B). In Fig. 3.7, this approach is illustrated by applying consecutively a short (2 s) 
pulse of ACh followed by a wash step and subsequently 5, 10 and 20 s ACh (300 
nM) pulses. 
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Fig. 3.7 Timed applications of neurotransmitters. Fast perfusion of an oocyte 
expressing nACh receptors channels with 300 nM ACh for different time periods. IACh 
was induced by consecutive ACh applications for 2, 5, 10 and 20 s. Short periods of 
ACh application (< 20 s) were achieved by successive application of neurotransmitter 
and wash (control) solution as illustrated in Fig. 3.2B. 
 
 
3.2 A new approach for the discovery of GABAA receptor ligands in plant and 
fungal extracts 
For screening and subsequent activity profiling of plant extracts we expressed 
GABAA receptors with the most abundant subunit composition (α1β2γ2S) in Xenopus 
oocytes. Extracts were applied to the oocytes by means of an automated fast 
perfusion system during two-microelectrode voltage clamp measurements.  
3.2.1 Screening a library of extracts 
The assay was first used for the screening of an extract library consisting of 704 
plant and fungal extracts. The outcome of this screening guided us in the subsequent 
development of this protocol. First of all, the number of extracts significantly 
enhancing chloride currents through GABAA receptors (defined as > 30% potentiation 
of IGABA at a test concentration of 100 µg/ml) was high (≈ 6% of extracts tested). 
Secondly, we also found a number (≈ 2%) of extracts significantly inhibiting IGABA (> 
30% at 100 µg/ml). Third, among the samples with stimulating effects were a number 
of extracts in which we suspected the presence of GABA at concentrations that could 
lead to false positive response.  
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3.2.2 HPLC-profiling of the active extracts 
Taking into account the requirements of the oocyte assay, we designed a protocol for 
HPLC-profiling of the active extracts, which included semi-preparative separation of 3 
to 10 mg of extract on a 10×150 mm column with gradient elution, and a time-based 
fraction collection (90 s per fraction). 
The applicability of the protocol was tested with plant extracts from the 
screening campaign. They were selected to contain structurally diverse compounds 
and provide a complex HPLC profile, in order to test the robustness of the assay and 
the applicability towards an accurate localization of activity. 
For a first test, we chose an EtOAc extract of Notopterygium incisum 
(Umbelliferae), which was essentially inactive in the initial extract screening (13.3 ± 
7.1% potentiation of IGABA, n = 3). The HPLC profile of a semi-preparative separation 
of 3 mg extract is shown in Fig. 3.8B (grey lines). Fractions of 90 s were collected, 
evaporated and tested after reconstitution. The corresponding activity profile is 
shown above and confirmed the lack of activity (maximal IGABA potentiation (27.4 ± 
14.9 %, n = 3) observed in the fraction 9 was not significantly different from zero, P > 
0.05, Fig. 3.8A, grey bars). 
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Fig. 3.8 HPLC-based activity profiling of the EtOAc extract from the roots of 
Notopterygium incisum and magnolol for GABAA ligand activity. The bar graphs (A) 
display potentiation of IGABA in % by the fractions collected from a single injection of 
the original extract of N. incisum (3 mg) (grey bars) and the spiked extract with 
magnolol (500 µg) (black bars). Magnolol, which is collected from an injection of the 
same amount under the same chromatographic condition, was used as control (a) for 
GABAergic activity. The HPLC chromatograms (B) show 20 fractions each which is 
separated by time-based fractionation (90 s). A single peak corresponding to 
magnolol (b) was shown at 16.77 min. (C) Representative current traces recorded 
from oocytes expressing GABAA receptors composed of α1, β2 and γ2S subunits in the 
presence of control GABA (EC3-10, single bar) and traces recorded during co-
application of GABA EC3-10 and fraction 11 (left column, double bar) or magnolol (300 
µM, right column, double bar). 
 
We then spiked the extract with 500 µg of the known GABAA ligand magnolol 
(Squires et al., 1999) and submitted it again to the microfractionation. The magnolol 
peak eluted under the given gradient profile at 16.77 min, directly after a UV-
absorbing peak of the inactive extract (Fig. 3.8B, b). The trace shows the 
chromatograms of extract spiked with 500 µg of the compound (300 µM 
concentration in the bioassay). The activity profiles are shown above in the same 
colour code (Fig. 3.8A, black bars). Comparison of IGABA potentiation by fraction 11 
(2038.9 ± 638.9%, n = 4) of the Notopterygium incisum extract spiked with 500 µg 
magnolol (see Fig. 3.8A) and the positive control, 300 µM magnolol (2111.3 ± 
659.3%, n = 4, Fig. 3.8A, a) revealed no significant difference. Typical chloride 
currents through GABAA receptors in control and during co-application of GABA and 
fraction 11 (Fig. 3.8C) and 300 µM magnolol (Fig. 3.8D) are shown. 
As a second example, we selected an extract of Valeriana officinalis 
(Valerianaceae) containing the subunit specific modulator valerenic acid (Yuan et al., 
2004; Khom et al., 2007). Besides valerenic acid, extracts contain a range of related 
diterpenoids, valepotriates and lignans (Schumacher et al., 2002; Navarrete et al., 
2006). The HPLC chromatogram of a pharmacologically active EtOAc extract of 
valerian and the corresponding activity profile are shown in Fig. 3.9. A major peak of 
activity (1370.4 ± 199.4% potentiation of IGABA, n=4, Fig. 3.9A) is seen in the time 
window 19.50 to 21.00 min, corresponding to the peak of valerenic acid at 19.72 min 
(Fig. 3.9B, a). Structurally related acetoxyvalerenic acid (14.95 min, Fig. 3.9B, b) 
identified by UV and ESI-MS data recorded on-line, was inactive (24.5 ± 6.3%, n = 4). 
This finding is in accord with data obtained from isolated compounds (Khom et al., 
2007). 
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Fig. 3.9 HPLC-based activity profiling of the EtOAc extract from the roots of 
Valeriana officinalis for GABAA ligands. The bar graphs (A) display potentiation of 
IGABA by the fractions collected from a single injection of valerian extract (10 mg). The 
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HPLC chromatograms (B) show 20 fractions each of which is separated by time-
based fractionation (90 s) after elution of DMSO. The peaks of valerenic acid (a) and 
acetoxyvalerenic acid (b) were shown at 19.72 min and 14.95 min, respectively. 
 
3.2.3 Determination of GABA-containing active extracts 
GABA may occur as the free amino acid in plant and fungal extracts and thus 
give false positive responses in the bioassay. Hence, an effective strategy for 
dereplication of GABA-containing active extracts was needed. Non-derivatized GABA 
itself is difficult to detect in an extract due to the complexity of the matrix, the polarity 
of the amino acid and its lack of a chromophore. Amino acid mixtures are usually 
analyzed after derivatization with OPA by RP-HPLC and fluorescence detection. 
First, we tested the conditions for derivatization and found that 50% aqueous 
methanol could be used equally well as water for dissolving the extract and the 
subsequent derivatization. This point was important in view of the handling of 
moderately polar extracts, which would be poorly soluble in water.  
As a next step, spiking experiments were carried out with the MeOH extract of 
Aeonium arboreum (Crassulaceae) that was free of measurable amounts of GABA. A 
typical chromatogram is shown in Fig. 3.10A2, together with the chromatogram 
recorded for the GABA reference (Fig. 3.10A1). The peak of spiked GABA and 
reference both eluted at 11.4 min.  
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Figure 3.10 HPLC chromatograms of OPA derivatives of GABA. Section (A) displays 
chromatograms of OPA derivative obtained from GABA reference (1) and the spiked 
extract (MeOH extract of Aeonium arboreum) with GABA (2), respectively. Both 
chromatograms showed a peak corresponding to GABA derivative (a) at the same 
retention time, 11.4 min. Section (B) shows chromatograms of crude extracts after 
derivatization with OPA. Crude samples are as follows; two plant extracts, Aeonium 
arboreum (1) and Cleome amblyocarpa (Capparaceae) (2), and two fungal extracts, 
Nomuraea rileyi RCEF 0291 (3) and Paecilomyces militaris RCEF 0720 (4). All the 
HPLC chromatograms were obtained at 340 nm. OPA derivative of GABA in the 
extracts (a) was detected based on the comparison of retention time and spectrum 
with OPA derivative of GABA reference. 
 
The calibration curves for derivatization in water and in 50% aqueous methanol 
were essentially similar and linear over a wide concentration range (5 µg/ml to 1 
mg/ml). The regression curves were y = 849582x–150332 (R2 = 0.9986) and y = 
878727x–53529 (R2 = 0.9991) in water and in 50% aqueous methanol, respectively. 
Limit of detection (LOD) (S/N ≥ 4) and limit of quantification (LOQ) (S/N ≥ 10) were 
estimated as 0.02 µg on column.  
 
Table 3.1 
GABA composition (mg/g of dry extract) in the crude extractsa 
GABA content (mg/g of extract) by OPA 
method Extracts 
H2O 50% aqueous MeOH 
Cleome amblyocarpa 4.54±0.06 3.93±0.04 
Paecilomyces militaris RCEF 
0720 
20.16±0.44 19.62±0.58 
Aeonium arboreum b nd nd 
Nomuraea rileyi RCEF 0291 2.07±0.04 1.87±0.04 
 
a GABA derivative in the extracts are identified by direct comparison of retention time and UV spectrum 
of GABA reference. Values are means of three replicates. 
b
 Not detected. 
Kim et al., 2008 
 
To elucidate if an extract contains interfering GABA we selected two pairs of 
plant and fungal extracts. GABA content in the extracts was determined by the OPA 
method (Fig. 3.10B and Table 3.1) as well as compared the IGABA enhancement 
during co-application of GABA and extract with the chloride current induced by the 
extract alone (i. e., in the absence of the agonist) (Fig. 3.11).  
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Fig. 3.11 Chloride currents in oocytes expressing GABAA receptors composed of α1, 
β2 and γ2S subunits induced by GABA (EC3-10, left column), during co-application of 
GABA EC3-10 and the indicated extract (middle column, double bar) and during 
application of the extracts alone (right column). The EC3-10 GABA concentrations 
were 10 µM (A–C). 
 
Enhancement of IGABA (EC3-10) by co-application of the MeOH extract of Cleome 
amblyocarpa (100 µg/ml) amounted 31.2 ± 8.8% (n = 4, Fig. 3.11A, middle trace). In 
the absence of GABA the extract induced a mean current with amplitude of 30.8 ± 
10.8% of the control IGABA (n = 3, see Fig. 3.11A, right trace). Correspondingly, a 
significant GABA concentration (4.54 ± 0.06 mg/g in H2O and 3.93 ± 0.04 mg/g in 
MeOH extracts) was detected by the OPA method (Table 3.1 and Fig. 3.10B). Similar 
observations were made for Paecilomyces militaris RCEF 0720 MeOH extract which 
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contained even higher amounts of GABA (≈ 20 mg/g, Table 3.1 and Fig. 3.10B) and 
induced larger chloride currents (125.6 ± 13.7% of IGABA potentiation (n = 3) vs. 50.9 
± 31.4% of the control IGABA (n = 3) when applied alone, traces not shown). A low 
GABA concentration (< 1 mg/g dry extract) was found in a MeOH extract of Aeonium 
arboreum (Fig. 3.10B and Table 3.1). This extract induced only a small current 
response (6.4 ± 3.5% of IGABA control, n = 3) compared to the enhancement of IGABA 
when the extract was co-applied (49.3 ± 0.7 %, n = 3, see Fig. 3.11B for typical 
chloride currents). MeOH extracts of Nomuraea rileyi RCEF 0291 (100 µg/ml) 
potentiated IGABA by 70.9 ± 10.9% (n = 3) when co-applied with GABA. In the 
absence of GABA the extracts induced mean current amplitudes of 9.4 ± 1.1% (n = 
4) of the control IGABA (see Fig. 3.11C for corresponding current traces). The small 
amount of GABA detected in the extract (Fig. 3.10B and Table 3.1) nicely agrees with 
the induced current. Thus, the enhancement of IGABA by Cleome amblyocarpa and 
Paecilomyces militaris RCEF 0720 may be explained by the presence of GABA in the 
extract whereas IGABA enhancement by Aeonium arboreum and Nomuraea rileyi 
RCEF 0291 was significantly larger (P > 0.05) than the current response induced by 
the extracts suggesting the presence of allosteric modulators. 
It was recently shown that valerenic acid (a GABAA receptor modulator isolated 
from Valeriana officinalis) induces chloride currents in the absence of the agonist 
(Khom et al., 2007). The current response upon application of an extract in the 
absence of GABA may, therefore, indicate the presence of a naturally occurring 
agonist.  
 
 
3.3 Investigating GABAA receptors comprising γ1 subunits 
3.3.1 Modulation of α1β2γ1 receptors 
To investigate the pharmacological properties of compounds interacting with α1β2γ1 
GABAA receptors we have analyzed the modulation of this GABAA receptor subtype 
by 21 compounds from 12 different structural classes comprising 1,4-
benzodiazepines (flunitrazepam, diazepam, flurazepam, midazolam, and triazolam), 
1,4-thienodiazepines (clotiazepam), 1,5-benzodiazepines (clobazam), 
imidazobenzodiazepines (flumazenil, bretazenil, and L-655,708), β-carbolines 
(DMCM), pyrazoloquinolines (CGS 9896), pyrazolopyridines (CGS 20625), 
imidazopyridines (zolpidem), triazolopyridazines (Cl 218,872), imidazoquinolines (Ru 
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31719), imidazopyrimidines (Ru 32698, Ru 33203 and Ru 33356) and quinolines (PK 
8165 and PK 9084). 
In a first step, GABAA receptors were activated by GABA concentrations 
corresponding to EC5-10 and drug effects were screened at a single concentration of 
1 µM. As illustrated in Fig. 3.12A (white bars), only the benzodiazepines triazolam, 
midazolam and diazepam, the thienodiazepine clotiazepam, the pyrazolopyridine 
CGS 20625 and the pyrazoloquinoline CGS 9896 induced an enhancement of > 20% 
at this concentration. The other compounds induced either a very small but 
statistically significant enhancement (zolpidem and bretazenil), no statistically 
significant effect (DMCM, Cl 218,872, clobazam, flumazenil, Ru 33203, PK 9084, 
flurazepam, L-655,708, Ru 31719, Ru 33356 and Ru 32698) or even an inhibition of 
GABA-induced chloride currents (flunitrazepam and PK 8165). Details are given in 
Table 3.2. 
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Fig. 3.12 (A) modulation of chloride currents through GABAA receptors composed of 
α1β2γ1 subunits by 1 µM (white bars), 10 µM (grey bars) and 100 µM (black bars) of 
the indicated compounds. Each value represents the mean ± S.E. from at least four 
oocytes and ≥ 2 oocyte batches. *, significantly different from zero (P < 0.05, t-test by 
ANOVA). (B) typical traces for enhancement of chloride currents through α1β2γ1 
channels by triazolam, clotiazepam and midazolam at EC5-10. Control currents 
(GABA, single bars) and corresponding currents elicited by co-application of GABA 
and the indicated compound (double bars) are shown. 
 
Table 3.2 
 
Modulation of the GABA-induced chloride currents by 1 µM concentration of the 
indicated compounds for receptors composed of α1β2γ1 subunits (second column) 
and α1β2 subunits (third column). 
Each value represents the mean ± S.E. of at least four oocytes from at least two oocyte batches. 
 
IGABA (EC5–10) Potentiation Compound 
α1β2γ1 α1β2 
 % 
Triazolam  82 ± 10* -21 ± 4* 
Clotiazepam  53 ± 8* -14 ± 2* 
Midazolam  43 ± 4* -20 ± 5* 
CGS 20625  42 ± 4* 20 ± 5* 
CGS 9896  24 ± 3* 16 ± 7 
Diazepam  20 ± 3* 2 ± 2 
Zolpidem  13 ± 3* -5 ± 3 
Bretazenil  10 ± 1* -1 ± 5 
DMCM  8 ± 4 4 ± 2 
Cl 218,872  6 ± 5 -10 ± 1* 
Clobazam  5 ± 2 7 ± 3 
Flumazenil  4 ± 3 13 ± 5 
Ru 33203  2 ± 2 -5 ± 5 
PK 9084  -3 ± 3 -6 ± 4 
Flurazepam  -5 ± 3 26 ± 4* 
L-655708  -7 ± 2 -8 ± 5 
Ru 31719  -7 ± 3 -10 ± 5 
Ru 33356  -7 ± 3 -2 ± 3 
Ru 32698  -8 ± 2 -5 ± 2 
Flunitrazepam  -11 ± 2* -9 ± 5 
PK 8165  -16 ± 2* -14 ± 2* 
 
* Difference from zero was calculated by ANOVA. 
Khom et al., 2006 
 
To search for compounds displaying low potency but high efficiency, all 
compounds were subsequently tested at higher concentrations (10 and 100 µM) (Fig. 
3.12A, grey and black bars). Modulation of GABAA receptors at low GABA 
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concentrations (EC5-10 close to “tonic concentrations”) can substantially differ from 
modulation at high concentrations (i.e., millimolar “synaptic concentrations”). We 
have, therefore, analyzed the effects of all 21 compounds at 1 mM GABA (Fig. 
3.13A). None of the compounds, however, substantially enhanced or inhibited IGABA. 
Representative chloride currents induced by 1 mM in the absence or presence of 1 
µM triazolam or CGS 20625 are shown in Fig. 3.13B. 
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Fig. 3.13 (A) Modulation of chloride currents through GABAA receptors composed of 
α1β2γ1 subunits at 1 mM GABA by 1 µM concentration of the indicated compounds. *, 
statistically significant differences from zero (P < 0.05, t-test by ANOVA). (B) Typical 
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IGABA flow through α1β2γ1 channels induced by 1 mM GABA in the absence (control, 
left traces) and presence of 1 µM triazolam and 1 µM CGS 20625. 
 
3.3.2 Contribution of α1β2 receptors 
Previous studies have clearly shown that the extent of the incorporation of γ subunits 
into heterologously expressed GABAA receptors may vary between oocyte batches 
and decrease with time (Boileau et al., 2002). To clarify whether the effects observed 
were caused by α1β2γ1- or by α1β2-comprising receptors, we analyzed the effect of 
these compounds on GABAA channels composed of α1β2 subunits. With the 
exception of CGS 20625 (+20 ± 5%), CGS 9896 (+16 ± 7%), flumazenil (+13 ± 5%) 
and flurazepam (+26 ± 4%), all compounds (1 µM) were either inefficient in 
enhancing IGABA or even induced significant inhibition (triazolam, clotiazepam, 
midazolam, Cl 218,872 and PK 8165; Table 3.2). 
For the most potent stimulators of the α1β2γ1 receptors triazolam, clotiazepam 
and midazolam, we also analyzed the inhibition of IGABA in oocytes expressing only 
α1β2 subunits at higher (10 µM) concentrations. Triazolam inhibited the GABA-
induced chloride flux in α1β2 receptors by -33 ± 4% (n = 12), clotiazepam by -30 ± 8% 
(n = 7) and midazolam by -31 ± 9% (n = 5) (experiments not shown). 
 
3.3.3 Comparing the effects of benzodiazepine site ligands on α1β2γ1 and 
α1β2γ2S receptors 
Triazolam, clotiazepam, midazolam and CGS 20625 were subsequently analyzed in 
more detail by comparing their effects on α1β2γ1 and α1β2γ2S receptors. Figure 3.14 
illustrates the concentration dependence of the enhancement of the currents (EC5-10) 
by triazolam, clotiazepam and midazolam. The EC50 value was determined by fitting 
the concentration-effect data to the Hill equation. Triazolam enhanced the maximum 
chloride current of α1β2γ1 receptors by 85% while displaying the highest potency 
(EC50 ≈ 90 nM) of all tested benzodiazepines. Clotiazepam elicited an enhancement 
of the GABA response of approximately 170% but had a 19-fold lower potency (EC50 
≈ 1.7 µM) than triazolam. Midazolam was more potent than clotiazepam (EC50 ≈ 1.2 
µM) but was 13 times less potent than triazolam, with a maximum enhancement 
(92%) comparable to triazolam. 
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Fig. 3.14 Concentration-effect curves for triazolam, clotiazepam, and midazolam on 
α1β2γ1 (●) and α1β2γ2S receptors (■) using an EC5–10 GABA concentration (EC50 
values are given in Table 3.2). Data points represent means ± S.E. from at least four 
oocytes from ≥ 2 batches. 
 
A comparison of the concentration-response data obtained on GABAA channels 
containing γ2S subunits with those from GABAA channels containing γ1 subunits 
reveals a 3-fold higher efficiency of triazolam, a 1.5-fold higher efficiency of 
clotiazepam and a 3.7-fold higher efficiency of midazolam on α1β2γ2S receptors. The 
ratio of the EC50 values for triazolam, clotiazepam and midazolam 50 1
2S50
EC (γ )
EC (γ )
 
 
 
 
reflect 4-, 9- and 8-fold lower potencies of these compounds for α1β2γ1 receptors, 
respectively (Table 3.3). The apparent EC50 values, maximum enhancement and the 
corresponding ratios for the benzodiazepines tested are given in Table 3.3. 
 
Table 3.3 
Potency and efficiency of triazolam, midazolam, clotiazepam and CGS 20625 for 
GABAA receptors composed of α1β2γ1 or α1β2γ2S subunits. 
The maximum enhancement (percentage of control) and EC50 values were calculated by fitting the 
data points to a standard concentration-response curve. Rightmost column represents ratios between 
EC50 values of α1β2γ1 and α1β2γ2S receptors. 
 
α1β2γ1 α1β2γ2S 
Compound 
EC50 
Maximum 
potentiation 
EC50 
Maximum 
potentiation 
50 1
2S50
EC (γ )
EC (γ )
 
 nM % nM %  
Triazolam 92 ± 17 85 ± 7 22 ± 3 253 ± 12 4.18 
Midazolam 1150 ± 259 92 ± 8 143 ± 88 342 ± 64 8.04 
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Clotiazepam 1681 ± 432 172 ± 24 184 ± 88 260 ± 27 9.14 
CGS 20625 23,712 ± 6,835 645 ± 55 11,220 ± 722 724 ± 25 2.11 
 
Khom et al., 2006 
 
3.3.4 Modulation of IGABA by triazolam, clotiazepam and midazolam at different 
GABA concentrations 
To gain insight into the mechanism of IGABA enhancement, we studied the GABA 
dose-effect curves in the absence and presence of the modulators. The results are 
shown in Fig. 3.15A-C. In control, the mean EC50 value for GABA was 39 ± 3 µM in 
α1β2γ1 receptors and 50 ± 3 µM in α1β2γ2S receptors. The three benzodiazepine 
receptor ligands shifted the dose-effect curves to the left without affecting the 
maximal response (Fig. 3.15). It is noteworthy that the drug-induced shift was more 
pronounced for α1β2γ2S than for α1β2γ1 receptors, reflecting the higher efficiency of 
these ligands on α1β2γ2S. 
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Fig. 3.15 Modulation of the GABA concentration-response curve of α1β2γ1 (left) and 
α1β2γ2S receptors (right) by 1 µM triazolam (A), 10 µM clotiazepam (B), and 10 µM 
midazolam (C). The corresponding mean EC50 values were 37 ± 2 µM (control), 26 ± 
4 µM (triazolam) for α1β2γ1 and 52 ± 7 µM (control), and 17 ± 3 µM (triazolam) for 
α1β2γ2S (A); 40 ± 8 µM (control), 25 ± 4 µM (clotiazepam) for α1β2γ1 and 50 ± 5 µM 
(control), and 19 ± 3 µM (clotiazepam) for α1β2γ2S (B); and 41 ± 6 µM (control), 22 ± 2 
µM (midazolam) for α1β2γ1 and 47 ± 11 µM (control), and 13 ± 6 µM (midazolam) for 
α1β2γ2S (C). 
 
3.3.5 Effect of the pyrazolopyridine CGS 20625 on α1β2, α1β2γ1 and α1β2γ2S 
receptors 
CGS 20625 elicited maximum enhancement of chloride currents through α1β2γ1 
receptors of approximately 645%, with a half-maximal enhancement occurring at 
approximately 20 µM (Fig. 3.16B). CGS 20625 thus represents a low potency but 
highly efficient positive modulator of α1β2γ1 receptors. This compound enhanced the 
GABA response of α1β2γ2S receptors with comparable efficiency (Imax(γ2S)/Imax(γ1) ≈ 
1.12) and was less efficient on α1β2 receptors (Fig. 3.16B). At higher CGS 20625 
concentrations (≥ 300 µM), we observed weaker enhancement of the GABA-induced 
chloride flux than at 100 µM for all subunit compositions (Fig. 3.16A,B). 
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Fig. 3.16 Modulation of IGABA by CGS 20625. (A) Typical IGABA recordings illustrating 
concentration-dependent modulation of GABA-elicited chloride currents through 
α1β2γ1-containing receptors. (B) Concentration-effect curves for CGS 20625 on 
α1β2γ2S (●),α1β2γ1 (▲) and α1β2 (■) receptors. EC50 values and corresponding Hill 
coefficient were the following: 11.2 ± 0.7 µM, nH = 1.8 ± 0.1 (●); 23.7 ± 6.8 µM, nH = 
0.9 ± 0.1 (▲); and 4.3 ± 1.2 µM and nH = 1.4 ± 0.2 (■), respectively. Each data point 
represents mean ± S.E. from at least four oocytes and ≥ 2 batches. IGABA at 300 µM 
were excluded from the fit. (C) Modulation of the GABA concentration-response of 
α1β2γ1 (left) and α1β2γ2S receptors (right) by 100 µM CGS 20625. The corresponding 
EC50 values were 39 ± 16 µM (control, ■) and 7 ± 2 µM (CGS 20625, ●) in α1β2γ1 
receptors and 56 ± 14 µM (control, ■) and 15 ± 3 µM (CGS 20625, ●) in α1β2γ2S 
receptors. 
 
3.3.6 Effect of flumazenil on α1β2γ1 receptors 
Flumazenil is a ligand of the BZD-binding site of α1β2γ2 GABAA receptors and 
competitively inhibits the enhancement of GABA-induced chloride currents by 
benzodiazepine agonists (Wafford et al., 1993). It was therefore interesting whether 
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this compound would also inhibit the effects of triazolam and clotiazepam on α1β2γ1 
receptors. 
Figure 3.17A,B (left), illustrates the inhibition by flumazenil of triazolam- or 
clotiazepam-induced IGABA enhancement in α1β2γ2S receptors. As shown on the right, 
the effects of triazolam or clotiazepam on α1β2γ1 receptors were not inhibited by 1 µM 
flumazenil. Moreover, we were unable to study possible antagonistic effects at higher 
concentrations, because flumazenil induced significant enhancement of IGABA in 
oocytes expressing α1β2γ1 subunits at 10 (22 ± 2%, n = 4) and 100 µM (64 ± 8%, n = 
4; Fig. 3.17C). 
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Fig. 3.17 (A, B) Effect of flumazenil on the enhancement of IGABA by triazolam and 
clotiazepam. The left graphs illustrate the enhancement of IGABA through α1β2γ2S 
receptors by triazolam and clotiazepam in the absence and presence of flumazenil. 
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The right graphs illustrate the lack of inhibition of IGABA through α1β2γ1 receptors. (C) 
Typical IGABA through α1β2γ1 receptors in the absence (GABA) and presence of the 
indicated concentrations of flumazenil. 
 
 
3.4 Estimating the efficiency of the BZDs on GABAA receptors comprising γ1 
or γ2 subunits 
Modulation by BZDs of chloride currents through GABAA receptors expressed in 
Xenopus oocytes is dependent on the incorporation of a γ subunit (Boileau et al., 
2002). On the one hand injection of increasing amounts of γ encoding cRNA (i.e. 
α1:β2:γ2S ratios of 1:1:3 or 1:1:10) gradually reduces GABA sensitivity and on the 
other hand the increased fraction of α1β2γ2S receptors results in an increased IGABA 
potentiation by BZDs. In order to quantify the relation between γ subunit-mediated 
inhibition of GABA sensitivity and BZD action we have analyzed modulation of 
GABA-induced chloride currents (IGABA) in a large population of oocytes injected with 
different mixtures (1:1:1; 1:1.3; 1:1:10) of wild type or mutated α1, β2, and γ2S or γ1 
GABAA receptor subunits, or γ2-β2-α1/β2-α1 concatenated constructs. Triazolam, 
clotiazepam and midazolam were chosen because these drugs modulate GABAA 
receptors incorporating γ2S and γ1 subunits (see Fig. 3.14), which would allow us to 
compare their action at different efficiencies. 
 
3.4.1 Modulation of IGABA by BZDs in oocytes expressing variable ratios of 
α1β2 vs. α1β2γ1 or α1β2γ2S receptors 
Figure 3.18A illustrates the effect of triazolam on the concentration-response curves 
of IGABA through GABAA receptors in oocytes injected with different ratios of cRNAs 
encoding for α1, β2 and γ2S subunits. A saturating concentration (1 µM) of triazolam 
shifted the GABA concentration-response curves leftwards without significant effects 
on the maximal response. Higher γ2S expression and thus, presumably higher γ2S 
incorporation resulted in reduced GABA sensitivity and larger triazolam-induced shifts 
of the GABA EC50 values (∆EC50(triazolam): 16 µM (cRNA ratio α1:β2:γ2S 1:1:1); 24 
µM (1:1:3); 50 µM (1:1:10, Fig. 3.18A, see also legend to Fig. 3.18 for individual EC50 
values).  
The typical pattern of IGABA modulation of an oocyte (α1:β2:γ2S cRNA ratio 1:1:3) 
is illustrated in Figure 3.18B. Triazolam enhanced IGABA predominantly at low GABA 
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concentrations corresponding to EC5-10 and had almost no effects at a saturating 
GABA concentration. Similar observations were made for α1β2γ1 receptors (Figure 
3.18C). 
 
 
 
Figure 3.18 (A) Typical GABA concentration-response curves of oocytes injected 
with cRNAs of α1, β2 and γ2S subunits (cRNA stoichiometry: 1:1:1, left panel; 1:1:3, 
middle panel and 1:1:10, right panel) in the absence (control) and presence of 1 µM 
triazolam. The corresponding EC50 values for 1:1:1 were 24 µM (control), 8 µM 
(triazolam), for 1:1:3: 38 µM (control), 14 µM (triazolam) and for 1:1:10: 71 µM 
(control), 21 µM (triazolam). (B) Corresponding IGABA through α1β2γ2S (1:1:3) 
channels modulated by 1 µM triazolam at indicated GABA concentrations. (C) GABA 
concentration-response curves of oocytes injected with cRNAs of α1, β2 and γ1 
subunits (1:1:1, left panel; 1:1:3, middle panel and 1:1:10, right panel) in the absence 
(control) and presence of 1 µM triazolam. The corresponding EC50 values for 1:1:1 
were: 21 µM (control), 12 µM (triazolam); for 1:1:3: 31 µM (control), 16 µM 
(triazolam); for 1:1:10: 66 µM (control), 29 µM (triazolam). Each graph in (A) and (C) 
represents one experiment on one oocyte. 
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3.4.2 Different efficiencies of IGABA potentiation in oocytes expressing α1β2γ1 or 
α1β2γ2S receptors 
Figure 3.18 illustrates that GABA potency (EC50) and IGABA modulation by triazolam 
were both dependent on the amount of γ2S (or γ1) incorporation (see also Boileau et 
al., 2002). These experiments confirmed that apparently higher γ expression and 
correspondingly lower GABA sensitivity were always associated with larger BZD-
induced shifts of the curves. In line with Boileau et al. (2002, 2003) we observed a 
higher GABA sensitivity at cRNA ratios 1:1:1 and 1:1:3 compared to 1:1:10. The 
range of GABA EC50s for a given cRNA ratio reflected differences in γ incorporations.  
EC50s of individual oocytes were plotted versus the BZD-induced shifts of the 
GABA concentration-response curves (∆EC50(BZD)s) (Fig. 3.19). For all three 
compounds applied at saturating concentrations we obtained a clear correlation 
between EC50s and ∆EC50(BZD)s. The slope factors for oocytes expressing α1β2γ1 
subunit receptors (1.8 ± 0.1 (triazolam, Fig. 3.19A), 1.6 ± 0.1 (clotiazepam, Fig. 
3.19B) and 2.3 ± 0.2 (midazolam, Fig. 3.19C)) were always higher than for oocytes 
expressing α1β2γ2S receptors (1.4 ± 0.1 (triazolam, Fig. 3.19D), 1.4 ± 0.1 
(clotiazepam, Fig. 3.19E) and 1.3 ± 0.1 (midazolam, Fig. 3.19F)). The regression line 
approached the ordinate in the range of the EC50 of α1β2 receptors. The data suggest 
that the slope factors may reflect the efficiency of IGABA potentiation for these 
compounds (see Table 3.4). For clotiazepam we estimated similar slopes for γ1- and 
γ2S-incorporating receptors (difference statistically not significant; P > 0.05) whereas 
for triazolam and midazolam the slopes of the regression lines for the two receptor 
subtypes were significantly different (P < 0.05). 
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Figure 3.19 Correlation between EC50 values of the GABA concentration-response 
curves (EC50s) of oocytes expressing α1β2γ1 receptors (A, B, C), α1β2γ2S receptors 
(D, E, F) and shifts of these EC50 values (∆EC50(BZD)s) by modulation of the GABA 
concentration-response curve by 1 µM triazolam (A, D), 10 µM clotiazepam (B, E) 
and 10 µM midazolam (C, F). α, β and γ subunit cRNA stoichiometries are 1:1:1, 
1:1:3 and 1:1:10. Correlation coefficients were 0.94 (triazolam), 0.94 (clotiazepam), 
0.94 (midazolam) (P < 0.0001 in all cases, α1β2γ1) and 0.97 (triazolam), 0.94 
(clotiazepam), 0.90 (midazolam) (P < 0.0001 in all cases, α1β2γ2S). Each data point 
represents one experiment on one oocyte. 
 
Table 3.4 
Comparison of slope factors and maximal potentiation by BZDs. 
α1β2γ1 α1β2γ2S 
BZD 
Slope 
*Maximum IGABA 
potentiation (%) Slope 
*Maximum IGABA 
potentiation (%) 
Triazolam 1.8 ± 0.1 85 ± 7 1.4 ± 0.1 253 ± 12 
Clotiazepam 1.6 ± 0.1 172 ± 24 1.4 ± 0.1 260 ± 27 
Midazolam 2.3 ± 0.2 92 ± 8 1.3 ± 0.1 342 ± 64 
 
*data from Khom et al., 2006 
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3.4.3 Pharmacological properties of concatenated subunits fit the extrapolated 
regression lines 
If the inhibition of GABA sensitivity caused by γ incorporation correlates with IGABA 
potentiation then complete γ incorporation in concatenated subunits is expected to 
result in larger EC50s. In order to test this hypothesis we first injected higher amounts 
of γ1 and γ2S subunit cRNA (1:1:20, see Figure 3.20, filled diamonds and filled stars). 
We obtained, however, only a non-significant (P < 0.05) further reduction in GABA 
sensitivity (α1β2γ1: EC50 = 61 ± 3 µM, n = 4 and α1β2γ2S: EC50 = 62 ± 4 µM, n = 4, see 
dashed lines in Fig. 3.20). Next we expressed a mixture of concatenated subunit 
constructs (γ2-β2-α1 and β2-α1, 1:1 ratio, Baumann et al., 2002) and analyzed the 
GABA concentration-response curves. Figure 3.20 compares the mean GABA 
concentration-response curves obtained for oocytes injected with cRNAs for α1β2 
(1:1, n = 6), α1β2γ1 (1:1:10, n = 24), α1β2γ1 (1:1:20, n = 4), α1β2γ2S (1:1:10, n = 27), 
α1β2γ2S (1:1:20, n = 4) or concatenated γ2-β2-α1/β2-α1 receptors (1:1, n = 18). In line 
with previous studies (Baumann et al., 2002) oocytes expressing concatenated 
subunits in Xenopus oocytes displayed a lower GABA sensitivity. The EC50 of 
concatenated subunits was substantially shifted to the right (EC50= 186 ± 13 µM, n = 
18, Figs 3.20 and 3.21). The EC50s and corresponding shifts of the concentration-
response curve (∆EC50(BZD)s) for all three compounds are shown in Fig. 3.21A-C. 
When EC50s and corresponding ∆EC50(BZD)s were added to the graph shown in Fig. 
3.19 (Fig. 3.21D-F) they fitted the extended linear correlation obtained for non-
concatenated subunits. 
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Figure 3.20 GABA concentration-response curves for oocytes expressing α1β2 
(cRNA injection 1:1), α1β2γ1 (1:1:10), α1β2γ1 (1:1:20), α1β2γ2S (1:1:10), α1β2γ2S 
(1:1:20) and γ2-β2-α1/β2-α1 (1:1) receptors. The corresponding mean EC50 values and 
Hill coefficients were α1β2 (1:1): 8 ± 2 µM, nH = 1.0 ± 0.2 (n = 6); α1β2γ1 (1:1:10): 48 ± 
3 µM, nH = 1.3 ± 0.1 (n = 24); α1β2γ1 (1:1:20): 61 ± 3 µM, nH = 1.5 ± 0.1 (n = 4); 
α1β2γ2S (1:1:10): 51 ± 3 µM, nH = 1.4 ± 0.1 (n = 27); α1β2γ2S (1:1:20): 62 ± 4 µM, nH = 
1.5 ± 0.1 (n = 4); γ2-β2-α1/β2-α1 (1:1): 186 ± 13 µM, nH = 1.3 ± 0.1 (n = 18). 
 
3.4.4 Calculation of EC50 and ∆EC50 of mixed population 
The EC50 values and BZD-induced shifts in GABA sensitivity in oocytes expressing 
mixed receptor populations (different fractions of high GABA sensitive α1β2 vs. low 
sensitive α1β2γ2S receptors) are described by the concentration-response curves for 
each receptor population by: 
⋅
=
 
+  
 
αβ
αβ αβ
αβ H
50,αβ
i N
R
EC
1 [GABA]
  /1/ 
and  
⋅
=
 
+  
 
αβγ
αβγ αβγ
αβγ H
50,αβγ
i N
R
EC
1 [GABA]
  /2/ 
where Rαβ and Rαβγ are peak IGABA currents (number of open channels in each 
population) at a given GABA concentration, iαβ and iαβγ - amplitudes of single channel 
 64 
currents, Nαβ and Nαβγ are numbers of channels characterized by EC50,αβ and EC50,αβγ 
- midpoints of concentration-response curves, Hαβ and Hαβγ - Hill coefficients. 
The total normalized IGABA is a weighted sum of partial current responses:  
= ⋅ + − ⋅total αβγ αβR F R (1 F) R    /3/ 
where F is the fraction (0 < F < 1) of current through γ-containing GABAA receptors at 
saturating GABA concentrations: 
⋅
=
⋅ + ⋅
αβγ αβγ
αβ αβ αβγ αβγ
i N
F
i N i N
. 
Under application of a saturating concentration of BZD the receptor population 
consists of two sub-populations:   
1) αβ receptors with unchanged EC50,αβ and Hαβ  
and   
2) modulated αβγ receptors with enhanced GABA sensitivity (midpoint - EC50,mod and 
Hill coefficient - Hmod): 
⋅
=
 
+  
 
mod
αβγ αβγ
mod H
50,mod
i N
R
EC
1 [GABA]
  /4/ 
The total current response is described now by: 
= ⋅ + − ⋅total mod αβR F R (1 F) R   /5/ 
The apparent midpoints of the GABA concentration-response curves (EC50) for 
oocytes expressing a given fractions (F) of α1β2γ2S receptors and the shift of this 
curve (∆EC50 (BZD)) at saturating concentrations of triazolam, clotiazepam and 
midazolam can be obtained by varying the fractions (F) from 0 to 1 by maximum 
likelihood. 
 
3.4.5 Estimation of α1β2 and α1β2γ2S receptor fractions 
In an independent approach we theoretically calculated the behaviour of a mixed 
population of GABAA receptors with a high (α1β2) and a low α1β2γ2S) GABA 
sensitivity. The total normalized IGABA is the weighted sum of partial current 
responses of the individual receptors and only α1β2γ2S are sensitive to 
benzodiazepines (see chapter “Calculation of EC50 and ∆EC50 of mixed 
population”). The simulated curves are shown in Fig. 3.21 (solid lines). In order to 
calculate the putative fractions of α1β2 and α1β2γ2S receptors for oocytes displaying 
different GABA sensitivity we made use of the concentration of half-maximal 
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activation of the simulated curve of αβ receptors (EC50,α1β2 = 8 ± 2 µM, n = 6, see 
also Sigel and Baur, 2000; Baumann et al., 2001) and EC50,α1β2γ2S (186 µM) of 
concatenated receptors and corresponding Hill coefficients (Hα1β2 = 1.0, Hα1β2γ2S = 
1.3) from our experiments (see Fig. 3.20).  
The maximum likelihood fit of the EC50 vs. ∆EC50 relation predicts 100% γ2S 
incorporation for the concatenated receptors (Fig. 3.21D-F). Our calculations 
suggest, however, that even at a 1:1:10 cRNA ratio the fraction (F) of current through 
α1β2γ2S receptors accounts for only between 50 and 70% of the total current. If we 
assume that the single channel currents through γ-incorporating receptors is n times 
larger than through α1β2 receptors then the fraction (f) of γ-incorporating receptors is 
given by ( )= − ⋅ −
Ff
n F 1 n
.  
This formula accounts for differences in single channel conductance. The 
frequency of openings and mean open time also influences mean conductance of 
both sub-populations. The equation describing concentration-response curve used in 
our calculation (see chapter “Calculation of EC50 and ∆EC50 of mixed population”) 
estimates the fraction of open channels that, in turn, reflects the mean open time of 
single channels at different GABA concentrations and thus accounts for differences in 
open time. Assuming a two times larger single channel conductance for α1β2γ2S 
receptors (i.e. n = 2, see Angelotti and Macdonald, 1993; Fisher and Macdonald, 
1997) and F ≈ 70% would predict f ≈ 54%. In other words, our analysis suggests that 
even under conditions where α1:β2:γ2S were injected at a ratio of 1:1:10 only about 
50% of the expressed receptors contain a γ2S subunit. This may explain the large 
difference in EC50s of concatenated and non-concatenated receptors (even at a ratio 
of 1:1:20, Fig. 3.20). 
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Figure 3.21 GABA concentration-response curves of oocytes injected with 
concatenated subunits (γ2-β2-α1/β2-α1) in the absence (control) and presence of 1 µM 
triazolam (A), 10 µM clotiazepam (B) and 10 µM midazolam (C). The corresponding 
EC50 values were: 158 µM (control), 34 µM (triazolam); 150 µM (control), 60 µM 
(clotiazepam); 132 µM (control), 43 µM (midazolam). EC50 values of the GABA 
concentration-response curves of oocytes expressing concatenated subunit 
constructs (γ2-β2-α1 and β2-α1 in 1:1 ratio) and ∆EC50(BZD)s induced by (D) 1 µM 
triazolam, (E) 10 µM clotiazepam and (F) 10 µM midazolam were added to the 
regression lines from Fig. 3.19D-F. Corresponding regression lines (dashed) were 
taken from Fig. 3.19D-F and extended towards the values of the concatenated 
subunits. Solid lines (D-F) represent the nonlinear fit of equations /1/-/5/ by the 
maximal likelihood. Calculated current fractions of γ-incorporating receptors (0, 50, 
70 and 100%) are indicated. Each graph in (A), (B), (C) and each data point in (D), 
(E), (F) represents one experiment on one oocyte. 
 
3.4.6 Relation between EC50 and ∆EC50(BZD) on a GABAA receptor mutant 
with reduced GABA sensitivity 
Larger slope factors of γ1- vs. lower slope factors of γ2S-containing receptors 
indicated that this parameter provides a measure of drug efficiency. In order to further 
validate the sensitivity of this parameter, we made use of a mutation known to induce 
a reduction (β2-R207C; located in the GABA-binding site) in GABA sensitivity (see 
also Wagner and Czajkowski, 2001; Wagner et al., 2004). GABAA receptors 
composed of α1 and β2-R207C subunits displayed a reduced GABA sensitivity (Fig. 
3.22A, EC50 for α1β2-R207C = 486 ± 81 µM, n = 6, see also Wagner et al., 2004). Co-
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expression of α1, β2-R207C with the γ2S subunit induced a further reduction of GABA 
sensitivity (Fig. 3.22A, EC50 for α1β2-R207Cγ2S = 3217 ± 378 µM, n = 18). A 
saturating concentration of clotiazepam (10 µM) significantly increased chloride 
currents at GABA EC5-10 (Fig. 3.22B). The corresponding correlation between 
individual EC50 values of the GABA concentration-response curves (EC50s) of 
oocytes expressing α1β2-R207Cγ2S receptors and shifts of these EC50 values 
(∆EC50(BZD)s) caused by three benzodiazepines is shown in Fig. 3.23D-F. The 
regression lines approach the EC50-axis in a range (460 – 587 µM, Fig. 3.23D-F) 
close to the EC50 of α1β2-R207C receptors (Fig. 3.22A). Figure 3.23A-C illustrate 
typical shifts of the dose-response curves by a saturating concentration of triazolam 
(1 µM) for different α1:β2-R207C:γ2S cRNA ratios (1:1:1 - ∆EC50 = 421 µM, A; 1:1:3 - 
∆EC50 = 948 µM, B; and 1:1:10 - ∆EC50 = 2900 µM, C; see legend to Fig. 3.23 for 
individual EC50 values). The slopes of regression lines were 1.1 ± 0.1 (triazolam), 1.1 
± 0.1 (clotiazepam) and 1.2 ± 0.1 (midazolam). Interestingly, the three BZDs 
enhanced IGABA at saturating GABA concentrations (10 – 100 mM) where peak 
currents in wild type receptors were almost not affected (compare triazolam action in 
Figs. 3.18 and 3.23). 
 
 
 
Figure 3.22 (A) GABA concentration-response curves of oocytes expressing α1β2-
R207C (1:1, EC50 = 486 ± 81 µM, nH = 1.2 ± 0.2, n = 6) and α1β2-R207Cγ2S (1:1:10, 
EC50 = 3217 ± 378 µM, nH = 0.9 ± 0.1, n = 18) receptors. (B) Representative traces 
for enhancement of IGABA through α1β2-R207Cγ2S. Control currents (GABA) in the 
absence of clotiazepam and corresponding currents elicited by co-application of 
GABA and clotiazepam are shown. 
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Figure 3.23 GABA concentration-response curves of oocytes injected with cRNA 
ratios of α1, β2-R207C and γ2S subunits of 1:1:1 (A), 1:1:3 (B) and 1:1:10 (C) in the 
absence (control) and presence of 1 µM triazolam. The corresponding EC50 values 
for 1:1:1 were: 827 µM (control), 406 µM (triazolam); for 1:1:3: 1945 µM (control), 997 
µM (triazolam); for 1:1:10: 3891 µM (control), 991 µM (triazolam). (D-F) Correlation 
between individual EC50 values of the GABA concentration-response curves (EC50s) 
of oocytes expressing α1β2-R207Cγ2S receptors and shifts of these EC50 values 
(∆EC50(BZD)s) caused by modulation of the GABA concentration-response curve by 
1 µM triazolam (D), 10 µM clotiazepam (E) and 10 µM midazolam (F). Correlation 
coefficients were 0.96 (triazolam), 0.98 (clotiazepam), 0.97 (midazolam) (P < 0.0001 
in all cases). Each graph in (A), (B), (C) and each data point in (D), (E), (F) 
represents one experiment on one oocyte. 
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4 DISCUSSION 
 
4.1 Novel automated screening system 
4.1.1 Automated “concentration jumps” 
The automated voltage-clamp of Xenopus oocytes is an efficient approach to drug 
discovery. Main goal was, therefore, to develop a screening system for oocytes, 
enabling automated applications of neurotransmitters in “concentration jumps” to 
Xenopus oocytes. In the chamber construction illustrated in Fig. 3.1, test solutions 
can be injected directly into the funnel without disturbing the measurements. The link 
between the perfusion chamber and the liquid handling system (illustrated in Fig. 
3.2A) that is operated by custom-designed software (Fig. 3.3) permits consecutive 
fast (“concentration jump”) and slow chamber perfusion modes (Fig. 3.6). 
The speed of solution exchange is illustrated by the rise time of currents through 
ligand-gated channels (Fig. 3.4B,C) and the decrease of potassium outward currents 
through Kv1.1 channels upon rapid increase of the extracellular potassium 
concentration (Fig. 3.5A,B). 
An increase of the onset rates of ligand-gated ionic currents was observed upon 
increasing the speed of chamber perfusion from 300 µl/s (89.9 ± 5.7 ms) to 600 µl/s 
(55.0 ± 1.3 ms) (see Fig. 3.4B,C). Further increasing the speed of solution exchange 
did not lead to significantly faster onset rates, suggesting that invaginations at the 
oocyte surface and/or the vitelline membrane cause a diffusion barrier. The 
measurements of ligand-gated currents and potassium current decay yielded 
comparable time courses (Figs. 3.4C and 3.5B). 
The diffusion from the funnel reservoir through the two inlets was negligible. 
This was achieved by optimizing the size of openings for microelectrodes in the glass 
cover and the vertical position of the oocyte in the chamber and by immediate 
perfusion of the chamber after filling the funnel (Fig. 3.1). Identical Kv1.1 current 
traces before, during, and after a “concentration jump” with a high-potassium solution 
(compare early current traces 1 and 2 and late current traces 2 and 3 in Fig. 3.5A) 
confirm that the diffusion of high-potassium solution from the funnel into the chamber 
is insignificant. Furthermore, as illustrated in Fig. 3.4B,C, we observed fast-rising 
phases of IACh, suggesting that solution exchange occurs with a sharply segregated 
liquid front. 
 
 70 
4.1.2 Progress compared to previous methods 
Previously described “concentration jump” techniques permit oocyte chamber 
solution exchange time in the range of 800 (Madeja et al., 1991), 120–200 (Hering, 
1998; Rettinger and Schmalzing, 2003; Khom et al., 2006) or even less than 100 ms 
(Madeja et al., 1997). Even faster perfusion rates are achieved by means of the small 
volume (≈ 15 µl) chamber described in Fig. 3.1. 
Earlier chamber constructions (Hering, 1998; Khom et al., 2006) had the 
disadvantage that the solution was applied laterally to the oocyte. The abrupt liquid 
flow during a “concentration jump” resulted in a “liquid hammer” effect, that is, the cell 
was hit from the side by the pressure impulse. Depending on the speed and duration 
of the liquid flow, this lateral pressure impulse can lead to translocations of the 
oocytes and disturbances of the measurements (Baburin and Hering, unpublished 
data). The new construction overcomes this problem by enabling vertical flow of test 
solution from the funnel reservoir through the two symmetrically arranged access 
channels towards the outlet under the oocyte chamber. Placing the oocyte on 
cylindrical pedestal substantially increased oocyte stability. 
Thus, the cylindrical holder for the oocytes and the outflow through an annular 
gap by operating precise pumps of a programmable pipetting robot are principal 
advantages compared to a previous design (Hering, 1998). The solution flow 
perpendicular to and towards the support surface (see also Rettinger and 
Schmalzing, 2003) enabled faster exchange rates compared to Hering (1998) (Figs. 
3.4B,C and 3.5B). 
In the automated oocyte perfusion system described by Joshi et al. (2004), test 
solutions are delivered from the bottom of the chamber to the oocyte. Test solutions 
and control solution are applied to a common inlet tube that is incorporated in the 
chamber holder. The solution exchange time of 400 ms is one order of magnitude 
slower than that achieved by the system described here. Our system permits timed 
and short drug applications (Fig. 3.7), which is particularly helpful if short periods of 
ligand applications are essential to prevent channel desensitization. 
 
4.1.3 Suitability for “medium-throughput” drug screening 
Compared to conventional systems where drug application is limited by the number 
of inlet tubes, the use of a pipetting platform enables testing of a larger number of 
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compounds. Once the oocyte has been placed manually in the chamber, the 
experiment runs automatically. The throughput will depend, however, on the physico-
chemical properties of the tested compounds (lipophilicity, etc.) and the 
corresponding length of periods required for washout between consecutive 
applications. The time for desensitization (in case of ligand-gated channels) or 
recovery from inactivation (voltage-gated channels) has also to be taken into account 
(see Materials and Methods). 
At perfusion rates of 300 µl/s, a single oocyte can tolerate more than 50 
“concentration jump” applications without substantial increase in leak current. 
Between 10 and 20 “jumps” are usually tolerated at higher rates (400 – 600 µl/s). The 
use of the system is simple and requires only little training as placement of the oocyte 
in the chamber and microelectrode impalements are performed in a similar way as in 
the conventional oocyte perfusion chambers. Automation and precise timing of the 
experiment reduce interoperator variability and improve the reproducibility of the 
data. 
 
 
4.2 HPLC-based activity profiling of plant extracts for the discovery of GABAA 
receptor ligands 
We have developed and validated an approach for effective screening and 
prioritization of extracts modulating GABAA receptor activity, dereplication of GABA 
containing extracts, and for rapid localization and identification of active secondary 
metabolites via an HPLC-based profiling. The protocol offers significant advantages 
in terms of speed and information content over previous classical preparative 
isolation guided by a receptor-binding assay. Localization of activity can be 
performed with a resolution matching that of the HPLC separation. The activity of 
valerenic acid was easily detected in the oocyte assay, and the lack of IGABA 
stimulation by acetoxyvalerenic acid and hydroxyvalerenic acid, which had been 
recently shown in a testing of pure compounds, could be confirmed (Khom et al., 
2007).  
Our screening of an extract library confirmed previous reports (Medina et al., 
1989) that the hit rate in an extract-based screening for GABAA ligands is high. 
According to current knowledge, this may be due to the frequent occurrence of GABA 
in extracts. Therefore, we propose that extracts stimulating chloride currents through 
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GABAA receptors in the absence of GABA are analyzed by HPLC for GABA. 
Derivatization of GABA with OPA reagent and HPLC analysis with UV detection at 
340 nm was sufficiently sensitive for our needs, even though the LOQ (0.2 mg/g 
GABA in a dry extract) was approximately 100-fold higher than that reported for 
fluorescence detection. The GABA sensitivity of the oocyte assay depends on the 
subunit composition of the respective GABAA receptor (range: 0.1 – 1 µM). In our 
assay protocol, this concentration corresponds to GABA contents between 
approximately 0.1 and 1 mg/g GABA in a dry extract. For a rapid dereplication, a 
semi-quantitative estimation with a single concentration reference corresponding to 
the maximal tolerable GABA concentration should be sufficient. The detection of 
extract induced chloride currents and simultaneous detection of significant amounts 
of GABA by the OPA method will, therefore, help to identify “false positive” 
responses. Extract induced currents may, however, alternatively indicate the 
presence of GABAA receptor agonists. We currently use this profiling protocol for the 
identification of GABAA receptor ligands with structures new for the target. 
 
 
4.3 Pharmacological properties of GABAA receptors containing γ1 subunits 
4.3.1 IGABA of α1β2γ1 subunit receptors is enhanced by some benzodiazepines 
and the pyrazolopyridine CGS 20625 
The 21 compounds tested comprised benzodiazepines and representatives of other 
structural classes of ligands of the BZD-binding site of GABAA receptors. In order to 
determine the most potent modulators of α1β2γ1 subunit receptors we first tested the 
compounds at a concentration of 1 µM. 6 out of the 21 compounds induced an 
enhancement of the GABA response (EC5-10) by more than 20% with the following 
order of potency: triazolam > clotiazepam > midazolam > CGS 20625 > CGS 9896 > 
diazepam. Zolpidem and bretazenil induced a small enhancement (≈ 13% and ≈ 10% 
respectively). The effects of DMCM, Cl 218,872, clobazam, flumazenil, Ru 33203, PK 
9084, flurazepam, L-655,708, Ru 31719, Ru 33356, Ru 32698 were not significantly 
different from control. In contrast, flunitrazepam and PK 8165 significantly inhibited 
the GABA-induced chloride flux. Application of higher concentrations (10 and 100 
µM) revealed a moderate enhancement at high concentrations (low potency 
modulation) by bretazenil, DMCM, flumazenil, Ru 33203, Ru 32698 and 
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flunitrazepam. All compounds were tested in the absence of GABA (data not shown). 
None of them induced measurable currents even at high concentrations (up to 100 
µM). 
Thus, the 1,4- benzodiazepines triazolam and midazolam, the 1,4-
thienodiazepine clotiazepam and the pyrazolopyridine CGS 20625 appeared as the 
most promising candidates for further detailed analysis. 
 
4.3.2 Contribution of the γ1 subunit to the enhancement of IGABA 
On injection of Xenopus oocytes with α, β and γ subunits not only receptors 
containing all three subunits are formed but possibly also receptors composed of α 
and β subunits, only (Boileau et al., 2002). To investigate whether the observed drug 
effects were due to effects on α1β2γ1 receptors or could also be explained by effects 
on α1β2 receptors, the effects of drugs on the latter receptors were also investigated. 
A comparison of drug effects on α1β2γ1 and α1β2 receptors revealed that the γ1 
subunit was essential for enhancement of IGABA by triazolam, clotiazepam and 
midazolam (Table 3.2) because these compounds at 1 µM concentration induced a 
significant (P < 0.05) inhibition by –21 ± 4% (n = 12), -14 ± 2% (n = 6), and -20 ± 5% 
(n = 6), respectively, of IGABA through α1β2 subunit receptors. In addition, the effects of 
several other drugs were clearly different in α1β2γ1 and α1β2 receptors. Thus, CGS 
20625, CGS 9896, diazepam, zolpidem and bretazenil exhibited an enhancement of 
IGABA that was higher in α1β2γ1 than in α1β2 receptors, supporting the importance of 
the γ1 subunit for the effects observed. Finally, Cl 218,872 and flurazepam exhibited 
effects in opposite direction in α1β2γ1 and α1β2 receptors, again supporting the 
conclusion that the drug effects observed on injection of oocytes with α1, β2, and γ1 
subunits were predominantly due to α1β2γ1 receptors (Table 3.2).  
Our finding that triazolam, clotiazepam and midazolam significantly inhibit IGABA 
through α1β2 receptors suggests that we might have underestimated the 
enhancement of IGABA in α1β2γ1 receptors by these drugs due to simultaneously 
occurring inhibition of α1β2 subunit receptors. The differential effects of various BZD-
binding site ligands on receptors composed of α1β2 subunits is highly interesting by 
itself and significantly extends previous evidence for the existence of a low affinity 
BZD-binding site at αβ receptors (Walters et al., 2000; Wafford et al., 1993; Thomet 
et al., 1999).  
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In order to determine the potency and efficiency (maximum ability to enhance 
the GABA (EC5-10 response) of the 3 most potent BZDs (Table 3.3) we studied their 
concentration-effect relations for receptors composed of α1β2γ1 subunits (Fig. 3.14). 
The 1,4- benzodiazepine triazolam displayed the highest potency (EC50 ≈ 90 nM), 
followed by midazolam (EC50 ≈ 1.2 µM) and the 1,4- thienodiazepine clotiazepam 
(EC50 ≈ 1.7 µM, Table 3.3). A comparison of the concentration-effect curves for these 
benzodiazepine type ligands with receptors composed of α1β2γ2S receptors revealed 
a significantly lower efficiency and potency for γ1-containing receptors (Fig. 3.14, 
Table 3.3). 
 
4.3.3 The pyrazolopyridine CGS 20625 displays the highest efficiency in 
enhancing GABA-induced chloride flux of α1β2γ1 subunit receptors 
CGS 20625 was identified as the most efficient compound in terms of maximum 
enhancement of the GABA-induced chloride currents through α1β2γ1 receptors (Fig. 
3.16). This compound induced a maximum enhancement of 645 ± 55% above control 
which is about 3.75-fold the enhancement achieved with clotiazepam (172 ± 24% 
above control), more than 7 times the enhancement induced by midazolam (92 ± 8% 
above control) or by triazolam (85  ± 7% above control), respectively (Fig. 3.14). CGS 
20625 had, however, an about 200-times lower potency for α1β2γ1 receptors (EC50 ≈ 
20 µM) than triazolam and a 10 – 20 times lower potency than the other 
benzodiazepines (Table 3.3). 
A closer inspection of the subunit composition specificity of CGS 20625 action 
revealed that this drug potentiates α1β2γ1 and α1β2γ2S receptors to an almost similar 
extent (Fig. 3.16B). A significantly lower efficiency on α1β2 receptors revealed, 
however, an essential role of a γ subunit. 
CGS 20625 at 300 µM caused less enhancement than at 100 µM in α1β2, α1β2γ1 
and α1β2γ2S receptors (Fig. 3.16B) suggesting that this compound might inhibit 
chloride currents at high concentrations. Similar behaviour was previously shown for 
the action of another pyrazolopyridine (tracazolate) on GABAA channels (Thompson 
et al., 2002). 
CGS 20625 thus represents a low potency (EC50 ≈ 20 µM) but high efficiency 
modulator of α1β2γ1 and α1β2γ2S subunit-containing receptors (Fig. 3.16B). This 
compound was almost nonselective for either γ1 or γ2 subunits. α1β2 receptors were, 
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however, stimulated by CGS 20625 to a significantly lesser extent (≈ 160%) as 
compared with α1β2γ2S(γ1) receptors (640 – 730%) (Fig. 3.16B).  
The competitive antagonist flumazenil (1 µM) inhibited IGABA enhancement of 
α1β2γ2S receptors but failed to affect the enhancement of IGABA through α1β2γ1 
receptors by triazolam and clotiazepam (Fig. 3.17, right panels). These data suggest 
that flumazenil exhibits either no or a very low affinity for the BZD-binding site of 
α1β2γ1 receptors or that flumazenil interacts with a binding site different from that for 
triazolam and clotiazepam at these receptors. The first conclusion is consistent with 
the observation that the affinity of flumazenil for its binding site was reduced about 
1000fold in GABAA receptors in which phenylalanine 77 of the γ2 subunit was 
mutated to the corresponding residue (isoleucine) of the γ1 subunit (γ2-F77I, 
Wingrove et al., 1997; Buhr et al., 1997; Ogris et al., 2004). At higher concentrations 
flumazenil displayed properties of a low affinity agonist on α1β2γ1 receptors (10 µM 
potentiated IGABA by 22 ± 2% and 100 µM by 64 ± 9%). 
In addition to flumazenil, the affinity of bretazenil, L-655,708, DMCM, zolpidem, 
Cl 218,872 and PK 8165 was drastically reduced to receptors containing the γ2-F77I 
point mutation (Ogris et al., 2004) as measured by [3H]flunitrazepam-binding studies. 
A low affinity of these compounds for α1β2γ1 receptors could have contributed to their 
small effects on these receptors observed in the present study. In contrast, 
replacement of phenylalanine (γ2-F77) by the corresponding isoleucine of the γ1 
subunit only weakly (2 – 7 fold) reduced the affinity of the classical 1,4-
benzodiazepines, of the 1,4-thienodiazepine clotiazepam, the 1,5-benzodiazepine 
clobazam, or the pyrazoloquinoline CGS 9896 (Ogris et al., 2004). The small (4 – 9 
fold) reduction in potency of triazolam, midazolam and clotiazepam for enhancing 
α1β2γ1 as compared to α1β2γ2 receptors could be explained by a reduced apparent 
affinity of these compounds for α1β2γ1 receptors underlining the importance of F77 for 
high affinity BZD binding (Buhr et al., 1997). For other compounds such as 
flunitrazepam (1 µM) we observed significant inhibition of IGABA in α1β2γ1 receptors 
indicating the importance of additional amino acids for drug binding and/or gating. 
The different efficiencies of triazolam, midazolam, clotiazepam and CGS 20625 
are explained by the different amounts of shifts of the GABA concentration effect 
curves (Fig. 3.15A-C, Fig. 3.16C). Larger shifts induced on α1β2γ2S receptors reflect 
the higher apparent efficiency.  
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In summary we systematically investigated 21 ligands of the BZD-binding site 
from chemically distinct classes in order to obtain insight in the pharmacological 
profile of GABAA receptors comprising a γ1 subunit. Triazolam was identified as a 
high-potency and CGS 20625 as a high-efficiency modulator of this receptor-subtype. 
Different potencies of triazolam, midazolam, clotiazepam and CGS 20625 can be 
explained by different shifts of the GABA dose-effect curve reflecting different 
apparent affinities of these compounds. 
 
 
4.4 BZD suppression of the γ2S(γ1)-mediated reduction in GABA sensitivity 
A linear correlation between the γ subunit-mediated suppression and BZD-induced 
increase of GABA sensitivity in α1β2γ2S and α1β2γ1 receptors is revealed. We made 
use of a statistical approach because direct evaluation of this relationship is 
complicated by variable γ incorporation even under conditions where high ratios of γ 
subunit cRNA relative to α1 and β2 are injected. Injection of higher cRNA ratio of 
α1:β2:γ2S than 1:1:10 induced only a slight further reduction in GABA sensitivity 
suggesting a nonlinear relationship between cRNA ratios and γ subunit incorporation 
(see 1:1:20 ratio in Figure 3.20 and also Boileau et al., 2002). We have therefore 
induced different γ expressions by injecting different cRNA ratios and analyzed the 
relation between γ-mediated inhibition and BZD-induced enhancement of GABA 
sensitivity. 
 
4.4.1 Slopes of regression lines are inversely related to BZD efficiency 
An initially observed trend that larger BZD-induced shifts of the concentration-
response curves (∆EC50(BZD)s) in oocytes expressing larger fractions of γ subunit-
containing receptors (induced by injection of increasing amounts of cRNA encoding 
for γ subunits, Figure 3.18) was confirmed by correlation analysis (Figure 3.19). The 
linear relationship between EC50 values and ∆EC50(BZD) suggests that BZDs reduce 
a γ subunit-mediated inhibition of GABA sensitivity. A slope of 1.0 would correspond 
to complete elimination of a γ subunit-induced inhibition of GABA sensitivity and 
BZDs would correspondingly shift the concentration-response curve of α1β2γ2S(γ1) 
receptors to the position of α1β2 receptors. The observation that the tested BZDs 
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never increased GABA sensitivity to that or above that of α1β2 receptors indicates 
that these drugs only partially can compensate for the γ subunit-induced inhibition. 
The estimated slope factors ranged from 1.1 ± 0.1 in α1β2-R207Cγ2S (triazolam, 
clotiazepam) to 2.3 ± 0.2 (midazolam) in α1β2γ1 subunit receptors. In order to 
evaluate the significance of the slopes we compared the slopes on oocytes 
expressing α1β2γ1 and α1β2γ2S subunit receptors. The present results support 
previously estimated maximal IGABA potentiation by midazolam (342 ± 64%) > 
clotiazepam (260 ± 27%) ≈ triazolam (253 ± 12%) for oocytes expressing α1β2γ2S 
receptors (see Fig. 3.14, Table 3.3) and indicate a reversed order of regression 
slopes (midazolam: 1.3 ± 0.1 < clotiazepam: 1.4 ± 0.1 = triazolam: 1.4 ± 0.1). 
Furthermore, steeper slopes of the regression lines for α1β2γ1 compared to α1β2γ2S 
receptors specify that midazolam and to a lesser extent triazolam and clotiazepam 
increase GABA sensitivity less efficiently in α1β2γ1 than in α1β2γ2S receptors (Figure 
3.19) which confirms our previous findings (see Fig. 3.14, Table 3.3). Taken together 
our data suggest that the slopes of the regression lines between ∆EC50(BZD)s and 
EC50s are inversely related to drug efficiency.  
The described approach is time consuming as it requires the injection of 
different cRNA ratios and the measurements of a large number of concentration-
response curves. Our experiments under different conditions (including different 
BZDs, γ subunits and a mutation in the β2 subunit, Figures 3.19, 3.21 and 3.23) 
revealed, however, that the regression lines intercept the Y-axis close to the EC50 of 
α1β2 receptors. This finding prompted us to evaluate the possibility to use the Y-
intercept and three randomly selected data points (cRNA ratio 1:1:10, Figure 3.19D-
F) for correlation analysis. The simplified procedure yielded regression lines with 
slopes that were statistically not significantly different from larger data sets (data not 
shown). 
The relevance of the slope factor was further evaluated making use of the 
mutation β2-R207C that is known to induce a more than 60-fold reduction in GABA 
sensitivity (Wagner et al., 2004). Figure 3.22A illustrates that co-expression of γ2S 
decreased the GABA sensitivity analogously to wild type receptors (Figure 3.20). The 
estimated slope factors (1.1 ± 0.1 (triazolam), 1.1 ± 0.1 (clotiazepam) and 1.2 ± 0.1 
(midazolam), Figure 3.23) were always smaller than in wild type (though only in the 
case of triazolam and clotiazepam that difference was significant, P < 0.05) 
suggesting even higher BZD efficiencies compared to wild type. 
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4.4.2 Concatenated receptor subunits fit the regression lines 
Forced γ2 subunit incorporation in oocytes was previously shown to be associated 
with a significant loss in GABA sensitivity compared to oocytes injected with 1:1:10 
cRNA ratios (Baumann et al., 2002, see also Figure 3.20, but see Baur et al., 2006). 
Here we show that the higher EC50s and corresponding ∆EC50(BZD)s of 
concatenated subunits fit the predictions of the regression lines of non-concatenated 
subunits (Figure 3.21D-F, closed triangles). The mean EC50 of the concatenated γ2-
β2-α1/β2-α1 subunits (Figure 3.20) corresponds to the data of Baumann et al. (2002). 
Lower GABA sensitivity and higher BZD efficiencies of concatenated subunits 
expressed in Xenopus oocytes may accordingly result from more complete γ 
incorporation (rather than from forced subunit arrangement or interactions). Our data 
suggest that the studied GABAA receptor composed of two concatenated constructs 
may represent a model of completely assembled receptor with intact GABA and 
benzodiazepine-binding sites. This hypothesis (based on the extrapolation of the 
regression line) (Figure 3.21) requires, however, further studies. 
These experimental data could be reproduced by a mathematical model 
describing BZD modulation in oocytes expressing different current fractions of high 
GABA sensitive α1β2 vs. low sensitive α1β2γ2S receptors. Maximum likelihood analysis 
predicted (in line with the experimental observations) a linear relationship which 
enables the calculation of a putative fraction of α1β2γ2S receptors at a given EC50 and 
∆EC50(BZD). This calculation had, however, to account for the different single 
channel conductance of the two receptor subtypes (Angelotti and Macdonald, 1993; 
Fisher and Macdonald, 1997). Interestingly these independent calculations 
reproduced not only the linear correlation but predicted the expected 100% γ2S 
incorporation for the concatemers and thus, would support the experimental findings 
obtained with the concatenated receptors and our conclusions. 
 
4.4.3 Percentage of α1β2γ2 receptors in oocytes expressing these subunits 
Boileau et al. (2002) have clearly demonstrated that injecting higher ratios of γ2 
subunit cRNA results in a purer population of α1β2γ2 subunit receptors. In addition, 
Boileau et al. observed a remarkable run down of benzodiazepine modulation, 
suggesting a decay of γ2 subunit-incorporating receptors over time after injection into 
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oocytes which makes it difficult to compare data from different labs. Furthermore, 
small changes in the applied effective GABA concentration (usually between EC3 and 
EC10) can substantially affect the apparent benzodiazepine efficiency, thus further 
confounding a calculation of the percentage of expressed α1β2γ2S receptors. The 
method suggested above for determining the slope of the regression line, however, 
also allows the determination of the percentage of α1β2γ2S receptors. After correction 
for single channel conductances – assuming a twofold difference in the single 
channel conductance of α1β2 and α1β2γ2S receptors (Angelotti and Macdonald, 1993; 
Fisher and Macdonald, 1997) – a 70% current ratio would correspond to about 50% 
of γ2S subunit incorporation. 
The regression slopes are independent from variations in expression of α1β2 vs. 
α1β2γ2S(γ1) fractions or variations in experimental conditions (GABA concentration). 
The statistical analysis described here is based on the different shifts of the 
concentration-response curves and, therefore, independent of these possible 
experimental errors. The low percentage of α1β2γ2S receptors formed under the 
conditions used, indicate that at least in the Xenopus oocyte system (but not 
necessarily in other heterologous expression systems or under native conditions) the 
efficiency of assembly of α1β2 receptors might be comparable to or even higher than 
that of α1β2γ2S receptors, resulting in comparable amounts of α1β2 or α1β2γ2S 
receptors even when high concentrations of gamma subunits are available. 
 
4.4.4 Implications for the mechanism of BZD action 
The different shifts in the GABA concentration-response curves for GABAA receptors 
with different subunit compositions or mutants can be interpreted in terms of a 
mechanism where BZDs increase the microscopic affinity of the GABA-binding site 
or, alternatively, by a mechanism where BZDs facilitate channel gating (e.g., Jones-
Davis et al., 2005). The second scenario is supported by previous findings 
suggesting that BZD-like modulators enhance the amplitude of the GABA response 
by stabilizing the open channel conformation (Downing et al., 2005; Rüsch and 
Forman, 2005; Campo-Soria et al., 2006).  
We are tempted to speculate that the BZD-induced IGABA increase reflects an 
increase in GABA efficacy (as defined by Colquhoun, 1998) by a direct transduction 
of the benzodiazepine effect to the channel region (Akabas, 2004; Ernst et al., 2005). 
An increase of efficacy from apparent low level (e.g., in mutant β2-R207C or 
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concatemers) would result in a resolvable increase of the maximal GABA response 
(“over-potentiation” of the BZDs on the α1β2-R207Cγ2S isoform or concatenated 
receptors) and a simultaneous shift of the concentration-response curve toward lower 
GABA concentrations (Figure 3.21A-C, Figure 3.23A-C) (Colquhoun, 1998; Downing 
et al., 2005; Rüsch and Forman, 2005; Campo-Soria et al., 2006). These theoretical 
considerations need, however, more experimental validation including the 
investigation of further mutations (e.g., in the putative GABA-binding site and/or pore 
region) and the use of BZDs with a broad range of efficiencies. 
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5 CONCLUSIONS 
 
1) An automated fast perfusion system for drug screening on voltage- and ligand-
gated ion channels during two-microelectrode voltage clamp experiments on 
Xenopus oocytes has been developed. Advantages of the method described 
in the present study compared to conventional oocyte perfusion systems are: 
• automated applications of the drug/neurotransmitter to the cell making use 
of the TECAN pipetting workstation; 
• small (≈ 100 µl) volume of applied/tested drug or neurotransmitter to avoid 
waste of valuable compounds; 
• a solution exchange time of about 50 ms enabling fast oocyte perfusion 
(“concentration jump” applications); 
• different perfusion modes and timed drug applications; 
• custom made operating software with a user-friendly interface that allows 
to create individual experimental protocols; 
• stable and reproducible over the time data; 
• “medium-throughput” drug screening. 
 
2) An approach for rapid HPLC-based profiling for new GABAA ligands of natural 
origin has been developed. The protocol has been validated by spiking 
experiments with inactive extract and the GABAA receptor ligand magnolol, 
and by profiling of active extracts such as valerian extract containing the 
known GABAA receptor ligand valerenic acid. For dereplication of GABA 
containing extracts, we established a rapid and simple procedure by which 
GABA is analyzed as OPA derivative by reversed-phase HPLC. This 
dereplication protocol was validated with plant and fungal extracts which had 
been previously tested active or inactive in the oocyte assay and with spiking 
experiments. 
 
3) 21 ligands of the BZD-binding site from chemically distinct classes have been 
investigated in order to obtain insight in the pharmacological profile of GABAA 
receptors comprising a γ1 subunit. Modulation of GABA-induced chloride 
currents was studied at GABA concentrations eliciting 5-10% of the maximal 
response. 
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• triazolam, clotiazepam, midazolam, CGS 20625, CGS 9896, diazepam, 
zolpidem and bretazenil at 1 µM concentrations were able to significantly 
enhance IGABA in α1β2γ1 receptors; 
• 1 µM of DMCM, Cl 218,872, clobazam, flumazenil, Ru 33203, PK 9084, 
flurazepam, L-655,708, Ru 31719, Ru 33356, Ru 32698 had no significant 
effect and flunitrazepam and PK 8165 inhibited IGABA; 
• the most potent compounds triazolam, clotiazepam, midazolam and CGS 
20625 were investigated in more detail on α1β2γ1 and α1β2γ2S receptors. 
The potency and efficiency of these compounds for modulating IGABA was 
smaller for α1β2γ1 than for α1β2γ2S receptors; 
• the effects of triazolam or clotiazepam on α1β2γ1 receptors were not 
inhibited by competitive antagonist Flumazenil at 1 µM. At higher 
concentrations flumazenil induced significant enhancement of IGABA in 
oocytes expressing α1β2γ1 subunits; 
• CGS 20625 displayed the highest efficiency by enhancing at 100 µM IGABA 
(α1β2γ2S) by 775 ± 17% vs. 526 ± 14% IGABA (α1β2γ1) and 157 ± 17% IGABA 
(α1β2) (P < 0.05). 
These data provide new insight into the pharmacological properties of GABAA 
receptors containing γ1 subunits and may aid design of specific ligands for this 
receptor subtype. 
 
4) Plotting EC50 versus BZD-induced shifts of GABA concentration-response 
curves (∆EC50(BZD)) of oocytes injected with different amounts of α1, β2 and 
γ2S(γ1) cRNA (1:1:1 – 1:1:10) revealed a linear regression between γ2S(γ1)-
mediated reduction of GABA sensitivity (EC50) and ∆EC50(BZD). The slope 
factors of the regression were always higher for oocytes expressing α1β2γ1 
subunit receptors (1.8 ± 0.1 (triazolam), 1.6 ± 0.1 (clotiazepam), 2.3 ± 0.2 
(midazolam)) than for oocytes expressing α1β2γ2S receptors (1.4 ± 0.1 
(triazolam), 1.4 ± 0.1 (clotiazepam), 1.3 ± 0.1 (midazolam)). Mutant GABAA 
receptors (α1β2-R207Cγ2S) with lower GABA sensitivity showed higher drug 
efficiencies (slope factors = 1.1 ± 0.1 (triazolam), 1.1 ± 0.1 (clotiazepam), 1.2 ± 
0.1 (midazolam)). 
 83 
Regression analysis enabled the estimation of BZD efficiency when variable 
mixtures of α1β2 and α1β2γ2S(γ1) receptors were expressed and provided new 
insights into the γ2S(γ1) dependency of BZD action. 
 
5) The method for determining the slope of the regression line also allowed the 
determination of the percentage of α1β2γ2S receptors. Assuming a twofold 
difference in the single channel conductance of α1β2 and α1β2γ2S receptors, at 
70% current ratio of γ2S-containig receptors our mathematical model predicts 
only about 50% of γ2S subunit incorporation. 
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